UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

[X]	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended July 31, 2013
	For the fiscal year ended July 31, 2014
[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
	For the transition period from _________ to ________
	Commission file number: 333-176736

Remmington Enterprises, Inc.
(Exact name of registrant as specified in its charter)
Nevada	45-2759045
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
7582 Las Vegas Blvd. S., Ste. 236 Las Vegas, Nevada	89123
(Address of principal executive offices)	(Zip Code)
Registrant’s telephone number: (702) 217-3964

Altovida, Inc.

(Exact name of registrant as specified in its charter)

Securities registered under Section 12(b) of the Exchange Act:
Nevada	45-2759045
Title of each class	Name of each exchange on which registered
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
none	not applicable
BioCity Scotland, Newhouse, Lanarkshire, UK	ML1 5UH
Securities registered under Section 12(g) of the Exchange Act:
(Address of principal executive offices)	(Zip Code)
Title of class
Registrant’s telephone number: +44 1698 53 9797
none

Securities registered under Section 12(b) of the Exchange Act
Title of each class	Name of each exchange on which registered
None	not applicable

Securities registered under Section 12(g) of the Exchange Act:
Title of each class
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ X] No [X ]

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X ] No [ X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

~~[ ]~~ Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [X ] No [ X]

State ~~the~~ the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of of the registrant’s most recently completed second fiscal quarter. ~~$600,000~~Not ~~as of January 31, 2013~~available.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. 1377,~~000~~650,~~000~~166 as of October 2822, ~~2013~~2014.

Table of Contents

TABLE OF CONTENTS
		Page
PART I
Item 1.	Business	3
Item 2.	Properties	8
Item 3.	Legal Proceedings	9
Item 4.	Mine Safety Disclosures	9
PART II
Item 5.	Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities	10
Item 6.	Selected Financial Data	11
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 8.	Financial Statements and Supplementary Data	14
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	15
Item 9A(T).	Controls and Procedures	15
Item 9B.	Other Information	15
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	16
Item 11.	Executive Compensation	18
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	20
Item 13.	Certain Relationships and Related Transactions, and Director Independence	20
Item 14.	Principal Accountant Fees and Services	21
PART IV
Item 15.	Exhibits, Financial Statement Schedules	21

TABLE OF CONTENTS

		Page
PART I
Item 1.	Business	3
Item 2.	Properties	6
Item 3.	Legal Proceedings	6
Item 4.	Mine Safety Disclosures	6
PART II
Item 5.	Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6.	Selected Financial Data	8
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	10
Item 8.	Financial Statements and Supplementary Data	10
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	11
Item 9A.	Controls and Procedures	11
Item 9B.	Other Information	11
PART III
Item 10.	Directors, Executive Officers and Corporate Governance
Item 11.	Executive Compensation
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	14
Item 13.	Certain Relationships and Related Transactions, and Director Independence	14
Item 14.	Principal Accountant Fees and Services	14
PART IV
Item 15.	Exhibits, Financial Statement Schedules	15

Table of Contents

PART I

Item 1. Business

~~Principal Place of Business~~Overview

~~Our principal~~We ~~offices~~ are ~~located~~a atrapidly ~~7582~~growing ~~Las~~biopharmaceutical ~~Vegas~~company ~~Blvd.~~focused ~~S.,~~on ~~Ste~~the development and commercialization of medicines in areas of real clinical need. ~~236~~Currently, ~~Las~~we ~~Vegas,~~operate ~~Nevada~~through ~~89123. Our~~our ~~officer~~wholly-owned ~~and~~subsidiary, ~~director~~Altovida ~~provides office~~Biosciences ~~services~~Limited ~~free~~based ofin ~~charge~~Scotland, UK.

InWe make ~~General~~medicines that make a real difference to patients’ quality of life and believe we adopt a unique approach to management of the risks associated with drug development. We do this in two ways, by the sale of a portfolio of commercial drugs which we market predominantly in the European markets and our pipeline of soon to market drug development projects. Whilst the commercial products offer the opportunity for revenue growth, the main thrust of the business is to complete the development of high-value projects and commercialize them in the main global markets (initially through partners), with a priority focus on the USA and Europe.

~~We are an~~The ~~exploration~~current ~~stage~~development ~~company~~portfolio ~~engaged~~includes in5 ~~the~~high-value, ~~exploration~~relatively oflow-risk ~~mineral~~medicines ~~properties. We~~which ~~have~~we ~~acquired~~are aworking ~~block~~to ofbring ~~mineral~~to ~~claims~~market in ~~that~~the weUS ~~refer~~and toEurope aswithin ~~the~~our ~~Remington~~current ~~claims~~planning period. ~~The~~ ~~claims~~Of ~~are~~these ~~formally~~we ~~designated~~have astwo ~~Remington~~lead ~~#1,~~projects: ~~Remington~~ALT022 ~~#2, Remington #3,~~ and ~~Remington #4~~ALT025. ~~The~~ ~~claims~~These medicines are auto-injector ~~identified~~versions ~~as, Bureau~~ of ~~Land~~naloxone ~~Management~~(for ~~Nevada~~the ~~Mining~~treatment ~~Claim~~of ~~Nos.~~opioid ~~NMC~~overdose) ~~1035534, NMC~~and ~~1035535,~~midazolam ~~NMC~~(for ~~1035536,~~sedation and ~~NMC~~the ~~1035537~~treatment of acute seizures), respectively.

~~Additional~~Cost ~~exploration~~from ofinitiation ~~our mineral claims is required before a final determination as~~ to ~~their~~registration ~~viability can be made. The property consists of approximately 100 acres and~~ is ~~located~~very onlow ~~federal land in Mineral County, Nevada. The Remington claims are a lode mining claims which were located on October 12, 2010. Mining claims on federal land are staked~~ by ~~the~~regular ~~placement~~pharma ~~of a discovery monument on the claim in a conspicuous place~~terms. In ~~Nevada,~~Time ~~notice~~to ofmarket ~~the claim location is then recorded with the county recorder~~ for ~~the county in which the claim is located. The Remington claims were~~ each ~~staked by the placement~~ of ~~discovery monument secured in a mound of stone on~~ the ~~claims. Notices~~lead ofprojects ~~the~~is ~~claim locations were then~~approximately ~~recorded with the Mineral County, Nevada recorder on January 10, 2011~~2.5 ~~The Remington claims are unpatented mining claims and our rights to the property are restricted to the exploration and extraction of a mineral deposit~~years. ~~See~~During ~~generally,~~that ~~“Compliance with Governmental Regulation~~time,” ~~below. We~~we ~~acquired~~plan ato ~~100%~~engage ~~interest~~ in ~~the~~development ~~Remington mineral claims on July 29~~activities, ~~2011~~ ~~for~~compile aregulatory ~~purchase~~dossiers price of $20,600. Our ownership was conveyed from the original locator by way of quitclaim deed which was recorded in Mineral County, Nevada, with copy being furnished to the Bureau of Land Management. We are the sole owner of the Remington claims and ~~there~~submit ~~are no royalty agreements or other contractual interests in the claims. Certain conditions must be met in order~~ for ~~our rights in the Remington claims to be maintained. All federal mining claimants must pay~~approval ~~an annual maintenance fee per claim or site~~ to the ~~BLM~~regulatory ~~(currently~~authorities ~~$140 per claim)~~(e. ~~Because we own an interest in 10 or fewer mining claims nationwide~~g., ~~we have~~ the option of performing assessment work in the minimum amount of $100 in labor or improvements on each claim, and recording evidence of such with the BLM by December 30 of the calendar year in which the assessment year endedFDA). ~~The charge for recording an affidavit of annual labor or representation with BLM is $10 per claim.~~

~~Through~~The ~~our~~founders ~~consulting geologist, we~~ have ~~performed~~so anfar ~~initial~~invested ~~reconnaissance sampling program on our mining claims~~$3. ~~Our~~4 ~~initial sampling~~million ~~program indicated the presence elevated silver mineralization~~ in the ~~rock~~company’s ~~outcrops which were sampled~~pipeline. ~~Based~~We ~~upon~~will ~~the results~~need ofto ~~our~~raise ~~initial~~capital ~~reconnaissance~~to ~~sampling~~bring ~~program,~~ our ~~consulting geologist has recommended an additional detailed rock sampling~~development ~~program,~~product ~~together~~portfolio ~~with geological mapping of the claims and a reconnaissance sampling of nearby properties on the boundaries of the Remington claims~~ to ~~determine if the acquisition of neighboring properties would be beneficial~~market. ~~Our~~We ~~planned~~raised ~~additional~~roughly ~~exploration activities~~$850,000 ~~will be designed~~ to ~~explore~~commence ~~for~~our ~~additional~~first ~~indications~~project, ~~that~~ALT022, ~~the~~but ~~Remington~~will ~~claims~~need ~~may~~an ~~contain~~estimated ~~commercially viable quantities~~$10 ofmillion ~~silver.~~in Weorder ~~have~~to ~~not~~commence ~~identified~~work ~~commercially exploitable reserves of silver or other precious metals~~ on ~~the~~all ~~Remington~~projects ~~claims to~~in ~~date. We are an exploration stage company and there is no assurance that commercially viable gold quantities exist on~~ the ~~Remington mineral claims~~pipeline. In ~~addition,~~If ~~our sole officer and director, Mr. Scoggins, has not yet visited the property. As a result,~~ we ~~may~~are ~~face~~unable anto ~~enhanced~~raise ~~risk~~these ~~that~~funds, ~~upon~~our ~~management’s~~plan ~~physical~~is ~~examination~~to ~~of the Remington~~finish ~~property,~~our nofirst ~~commercially~~project ~~viable~~and ~~deposits~~then ofcommence ~~gold~~subsequent orprojects ~~other~~with ~~minerals~~revenues ~~will~~generated befrom ~~located~~ALT022.

The ~~Remington~~ ~~property~~commercial isproduct ~~without~~portfolio ~~known~~includes ~~reserves~~proprietary medicines and ~~our~~recently ~~proposed~~in-licensed ~~program~~therapies. This is ~~exploratory~~supported by small scale, inexpensive in-house ~~nature~~manufacturing which ensures continuity of supply of these critical medicines and favorable product margins.

~~Location~~The ~~and Means of Access to the Remington Claims~~Company

~~The Remington~~We #1were -established 4to ~~claims~~provide ~~consists~~a ofsolid ~~four~~commercial ~~contiguous~~base ~~unpatented~~to ~~lode~~support ~~mining~~the ~~claims~~progression ~~covering~~of ~~approximately~~our ~~100~~high-value ~~acres~~drug incandidates. ~~Township~~Our 6goal ~~North,~~is ~~Range~~to 32involve ~~East~~very (Tlow ~~6N,~~staff Rnumbers ~~32E),~~relative ~~section~~to 7,typical ~~and~~pharma. ~~Township~~We 6believe ~~North,~~the ~~Range~~existence 33of ~~East~~a (Tsound ~~6N,~~commercial ~~R 33E)~~platform, ~~Sections~~along 8with low and 17tightly-maintained overheads, ~~Mount~~ensures ~~Diablo~~that ~~Base and~~invested ~~Meridian~~funds ~~(MDB&M). The mining claims~~ are ~~located~~focused on ~~Bureau~~expediting ofthe ~~Land~~approval ~~Management~~of ~~lands in Mineral County, Nevada, near Hawthorne, NV. Access to~~ the ~~claims is predominately on dirt roads that are in good condition. A 4~~high-value ~~wheeled drive is recommended, although~~development adrugs. ~~2-wheeled~~It ~~drive~~also ~~would~~allows ~~probably~~us ~~access~~headroom ~~the property~~ in the ~~absence~~event of ~~inclement~~unforeseen ~~weather. Directions~~issues ~~from~~in the ~~town of~~development ~~Hawthorne, NV are as follows with a GPS point at the end of the route:~~pathway.

·	From Hawthorne, NV, head East on US 95. Follow US 95 for approximately 8.6 miles.
·	Turn right onto Garfield Flats Road. Follow Garfield Flats Road and Garfield Road for approximately 37.6 miles.

We have a steady flow of product opportunities, both commercial and development since all of our concepts originate in the Clinic. It is through years of close contact with clinicians, patients and advocacy groups that we have built up a portfolio of genuinely needed products. In short, we listen to the market. As such we are able to live true to our motto ‘Seek the answer’. We start with a clinical problem identified by the medical community and we then explore every avenue to solve the problem pharmacologically. If the resultant medicine has the potential to garner defensible IP, it is selected for full development; if not it becomes a commercial product. By adopting this approach, we believe we are already seen as a true partner by the medical community we serve.

·	Turn right at the fork onto un-named two-track road and follow for 1.5 miles. Go left at the fork, ending GPS point is 38.23262 N., 118.19981 W. (Note: The GPS units are decimal degrees (DD.ddddd) and the datum is NAD27)
·	The two-track road winds up a narrow wash and stops at an elevation of about 5840’. It is a short hike up to the claims. There is no direct vehicle access to the claims.

Development Strategy

We adopt a unique approach to managing the risks associated with drug development. Big Pharma has traditionally been supported by the investment of billions of dollars in drug discovery where very few molecules from the millions screened make it through to become, often blockbuster, medicines. Specialty Pharma adopted an approach that removed the need for discovery by utilizing existing known, off-patent molecules in different ways or for different therapeutic indications. This means that these companies are not required to carry out expensive pre-clinical safety studies as the safety profile of the molecule has often been established for many years. These medicines, whilst they do not commonly achieve blockbuster status, regularly go on to sell profitably having utilized a fraction of the R&D budget attributable to their Big Pharma cousins. More often than not, these companies identify themselves by a therapeutic niche (e.g. ‘the neurology company’) or by some proprietary IP by way of formulation technology or a device, for example.

Our approach is different in that we begin with the medical challenge, not the IP/molecule and we are never restricted by therapy area or delivery method. In doing so, we mitigate the risk of changes in clinical practice within a single therapy area and open up to a wider IP portfolio, whilst a commercial need is ensured. Essentially the company takes the medical challenge, ascertains which existing molecule should be effective once in the body, then works out the best method of administration. This sounds simplistic however so many other considerations get in the way of this being the standard methodology in drug development.

For us, there must be enough evidence reported in the literature (usually lead by interested clinicians) to support the use of the molecule in the proposed indication. This gives the company confidence that any clinical trial will be successful prior to investing in it. It also helps provide bibliographic support for our applications to the authorities. For our lead candidates, the molecules are already licensed in the key territories, for the intended indications; we propose to provide them in fit-for-purpose presentations for the first time. This minimizes the regulatory burden of proof. Furthermore, the therapeutic indication for these first two candidates involves binary clinical outcomes; they either work or they don’t, there is no sliding scale.

Table of Contents

~~Acquisition and Ownership of the Remington Mineral Claims.~~Products

~~We have~~Development acquired a 100% interest in the Remington mineral claims on July 29, 2011 for a purchase price of $20,600. Our ownership was conveyed from the seller by way of quitclaim deed which was recorded in Mineral County, Nevada, with copy being furnished to the Bureau of Land Management. All federal mining claimants must pay an annual maintenance fee per claim or site to the BLM (currently $140 per claim). Because we own an interest in 10 or fewer mining claims nationwide, we have the option of performing assessment work in the minimum amount of $100 in labor or improvements on each claim, and recording evidence of such with the BLM by December 30 of the calendar year in which the assessment year ended. The charge for recording an affidavit of annual labor or representation with BLM is $10 per claim.Projects

~~History~~Lead ~~of Previous Mining Operations on the Remington Claims and Condition of the Property~~Projects

The Remington lode claims include the historic workings of the Rock Cabin Mine, which is located at the southeastern extent of an extensive northwest / southeast mineralization trend. Historic workings are dotted throughout the claim block and consist of several small digs, shafts and prospects. One particular tunnel had been excavated to more than 60 feet deep and several have been timbered. Many of the historic workings are shallow, however, or were excavated to a few tens of feet below the surface. The small prospects, digs and shafts explore alterations on the Remington claim block. The claims were originally laid out to maximize the coverage of these prospects. The historic Rock Cabin Mine was a producer of gold, silver, lead and tin. Silver production is more prevalent in the southern half of the mining district that includes the Remington lode claims. There are no historical production records available for silver or other metals on the claim.ALT022

~~The Remington~~Responding #1to ~~- #4 lode claims are located in~~ the ~~Garfield~~rapidly ~~Hills~~increasing ~~near~~levels ~~Garfield~~of ~~Flat.~~prescription ~~The~~opioid ~~property~~use ~~occupies a northwest-southeast trending ridge that slopes fairly steeply down~~ in ~~all~~Western ~~directions.~~countries, ~~The~~we ~~elevation~~are ~~ranges~~developing ~~from~~an ~~5920’~~easy to ~~6158’~~use, ~~amsl. It contains~~intramuscular ~~arid,~~naloxone ~~high~~auto-~~elevation~~injector. ~~vegetation~~Naloxone ~~consisting~~is ~~predominantly~~an ofopioid ~~sagebrush~~receptor ~~and~~antagonist ~~various~~that ~~grasses~~can ~~and~~rapidly ~~shrubs.~~reverse ~~The~~the ~~claims~~overdose ~~occupy~~of ~~the~~either ~~crest~~prescription of(e.g. aOxyContin) ~~north-northwest~~or -illicit ~~south-southeast~~(e.g. ~~trending~~heroin) ~~rocky peninsula to the Garfield alkali flats~~opioids.

~~There~~Prescription opioid use is becoming more prevalent globally, particularly in the USA. Nearly 257 million prescriptions for opioids were written ~~currently~~in nothe ~~electrical~~USA ~~power~~in ~~available~~2009 onalone. While prescription opioids such as OxyContin and Vicodin are needed to treat chronic pain, abuse rates have also risen and overdose mortality rates closely correlate with opioid sales. In 2008, approximately 36,450 people died from drug overdose in the ~~Remington~~USA. ~~claims~~At least 14,800 of these deaths involved prescription opioids (FDA, 2012). Moreover, according to the Substance Abuse and Mental Health Services Administration, the number of Americans in 2009 aged 12 and older currently abusing pain relievers has increased by 20% since 2002.

~~Work~~Revenue ~~Completed~~from the project is expected to ~~Date~~be ~~and~~realized ~~Planned~~from ~~Geological~~the ~~Exploration~~point ~~Program~~of out-license, anticipated Q4 2015/Q1 2016.

Our consulting geologist, Charles P. Watson, CA Professional Geologist #7818, has performed a reconnaissance-level mineral assessment of the property to outline its potential for an economically viable mineral deposit. The project consisted of the reconnaissance of historic prospects on the property and the collection of five representative rock samples. Sample descriptions were prepared, photographs taken and GPS positioning was determined. The samples were transported under chain of custody to ALS Minerals in Sparks, Nevada, a professional mineral testing and assaying facility. The testing result certificates were sent directly to the professional geologist, whereupon they were evaluated. The specific assay test involved a 35-element suite that used an aqua regia digest followed by an ICP analysis. In addition, a 30-gram sample was fire assayed for gold.ALT025

~~A summary~~This product is an intramuscular auto-injector of midazolam, initially for sedation with the ~~results~~main islife-cycle ~~presented~~extension incoming ~~Table~~from an 1,epilepsy ~~below:~~indication.

Table 1
Sample Description	Au ppm	Ag ppm	Cu ppm	Pb ppm	Zn ppm
RC-1	0.033	0.3	9	9	68
RC-2	0.109	14.4	143	5,660	1,755
RC-3	0.431	115	3,020	28,500	34,000
RC-4	0.012	6.7	286	2,980	2,030
RC-5	0.612	175	2,360	55,300	7,400

Health services often manage agitated or violent people and such behavior is particularly prevalent in emergency psychiatric services and general emergency departments. In the UK alone, the National Health Service (NHS) deals with more than 150 aggressive/violent patients every day at a cost of $170 million per annum. Guidelines recommend that these patients should be calmed by the use of words and reassurance, however, the acute danger of the situation (to staff, the patient and others) often makes this impossible. To ensure the safety of everyone involved, rapid tranquilization of aggressive or violent patients is often unavoidable. Drugs used in the setting include the benzodiazepine midazolam.

~~Laboratory~~We ~~results~~are ~~confirmed~~developing ~~field~~a ~~observations~~single use auto-injector presentation of ~~results~~midazolam for ~~high-grade~~use ~~silver~~in ~~and~~this ~~base~~setting. ~~metal~~The ~~mineralization~~main ~~occurs~~advantage onof the ~~property. Two~~auto-injector ~~samples,~~in ~~RC-3~~this ~~and~~setting ~~RC-5~~is ~~reported~~speed ~~over~~and ~~100~~ease ~~ppm~~of ~~silver~~use ~~with~~versus adrawing ~~peak~~up ~~silver~~and ~~assay~~managing ofan ~~175~~injection ~~ppm~~via ~~(5.6~~syringe, ~~OPT).~~particularly ~~The~~if ~~highest~~the ~~silver assays came~~patient ~~from~~is ~~samples~~being ofrestrained ~~the~~but ~~quartz~~unlikely ~~veining~~to ~~mineralization~~be ~~where~~still. ~~intense~~Of ~~solution~~equal ~~boiling~~import ~~was~~however ~~noted.~~is Athe ~~key~~reduced ~~item~~risk of ~~note~~needle ~~was~~stick ~~the~~injury. ~~high~~This ~~silver values~~is ~~are~~a ~~also~~phenomenon where ~~associated~~the ~~with~~person ~~elevated~~administering ~~lead.~~the ~~Zinc~~injection ~~appears~~accidentally tothen bestabs athe ~~non-pathfinder~~needle ~~mineral~~into asthemselves itor ~~was~~a ~~high~~colleague, inplacing ~~RC-3~~each ~~and relatively~~at ~~low~~risk inof RCinfection/cross-5contamination. ~~Modest~~This ~~amounts~~is ofparticularly ~~copper~~an ~~were~~issue ~~also~~with ~~reported,~~a ~~and~~moving ~~these~~patient. ~~two~~The ~~samples~~needle ~~showed~~of the ~~highest~~auto-injector ~~values~~retracts immediately ~~for~~when the ~~five~~device ~~samples collected.~~has ~~Interestingly,~~finished ~~gold~~delivering ~~was~~the ~~also~~dose ~~highest~~of indrug ~~these two samples, showing 0.4~~ and ~~0.6~~cannot ~~ppm,~~then ~~respectively.~~physically ~~Although~~be ~~not impressive, it is noteworthy~~removed.

~~The two~~It ~~perimeter~~is ~~iron~~proposed ~~oxide mineralization samples collected, RC-1 and RC-2, showed promising silver results in RC-2. Considering~~ that ~~surface~~ ~~leaching~~an ofepilepsy ~~silver~~indication is ~~common,~~sought itfor ~~suggests~~ALT025 ~~that~~following ~~higher~~its ~~silver~~approval ~~values~~for ~~could be found at depth~~sedation. ~~Proportionally,~~This ~~lead~~will ~~was also~~extend ~~elevated in RC-2, which supports~~ the ~~silver-leaching~~regulatory life ~~hypothesis. Further reconnaissance~~ of ~~these~~the ~~areas~~product ~~has~~and ~~been~~may ~~recommended by~~realize ~~our~~significant ~~consulting~~additional ~~geologist~~annual sales.

Pipeline

We have a pipeline of projects with similar development strategies to our lead projects. Development of these may start as soon as cash-flow allows, however they are planned to commence after the initial return of revenue from ALT022 or if we are successful in raising additional funds through outside investments.

ALT011

Despite being one of the most common medical conditions, potentially life threatening and having associated healthcare costs of c$6.9bn per annum in the USA alone, there have been very few new treatments for constipation in the last 30 years. With our product, aimed at non-USA markets, we intend to change that.

ALT024

Aimed at all global markets, this is a product which we believe offers a significant step forward in the treatment of Amyotrophic Lateral Sclerosis (ALS) benefitting both patients and caregivers.

ALT013

With increased awareness and better diagnosis, Parkinson’s disease (PD) is now the 2nd most common neurodegenerative disorder after Alzheimer’s disease. Treatment options are limited currently and can be difficult. ALT013 represent a paradigm shift in PD therapy.

Table of Contents

~~Based on~~Commercial the results of the initial Phase 1 reconnaissance sampling program, our consulting geologist has recommended taking additional steps in an exploration plan to explore for commercial silver deposits on the Remington claims.Products

~~Recommendations~~We currently sell a range of proprietary medicines, predominantly in the EU. These include Suptamid®, a buccal midazolam used for ~~additional~~the ~~sampling~~treatment of convulsive seizures, Glysmag® used for the treatment of hypomagnesaemia and ~~testing~~Mitonin® ~~include:~~used primarily for the treatment of insomnia.

·Recently acquired ~~Additional~~products ~~prospects~~include SPC Flakes® and Salovum®, both of which are ~~observed~~used ~~around~~to treat the ~~boundaries~~symptoms of Meniere’s Disease. Crucially, however these products have shown remarkable efficacy in the ~~Remington~~treatment ~~claim~~of ~~block~~Crohn’s Disease and other types of Inflammatory Bowel Disease/Syndrome. ~~These~~Their ~~prospects~~efficacy ~~should~~surrounds bethe ~~sampled~~effect on anti-secretory factor, ~~assayed~~which ~~and~~is ~~acquired~~being ~~through~~investigated in ~~additional~~relation ~~claim~~to ~~staking~~a ifnumber ~~positive~~of ~~results~~exciting ~~are~~possible ~~returned~~disease treatments. Altovida has the rights to the UK.

·To ensure ~~Vicinity~~growth and ~~detailed~~to ~~local~~drive ~~geological~~profitability, ~~mapping~~we ~~should~~have benew ~~conducted~~proprietary ~~with~~products ~~particular~~to ~~attention~~bring ~~paid~~through toand ~~the~~will ~~alteration~~in-license ~~suites~~key medicines from third parties as an ongoing process.

~~· Conduct a detailed rock sampling program with between 100-200 samples to better define the alteration suites, their spatial distribution and level of surface mineralization.~~Manufacturing

·We are ~~Begin~~currently ~~the~~finalizing ~~permitting~~a ~~process~~small ~~for~~scale ~~subsurface~~manufacturing ~~mineral~~capability ~~sampling~~in ~~through~~the ~~exploration~~UK ~~test~~to ~~pits~~both ordevelop ~~through~~and ~~dozer~~manufacture ~~cuts~~our current range of proprietary medicines. ~~Planning~~In ~~should~~due ~~also~~course ~~address~~we ~~the~~believe ~~possibility~~this will expand to both develop and produce higher batches of ~~using~~our ~~the~~most ~~disturbance~~common lines inas ~~the~~well ~~anticipation~~as initiating newer high barrier to entry brand lines to broaden our range, improve our margins and ensure continuity of supply. These include a ~~future~~wide ~~diamond~~range ~~drill~~of ~~program~~sterile pharmaceutical preparations identified as high need medicines in key territories such as Europe.

The Phase I reconnaissance sampling program was completed at a cost of $5,000. As discussed in more detail under “Management Discussion and Analysis of Financial Condition and Results of Operations,” below, we currently plan to pursue a sampling and mapping program on the property at an approximate cost of $20,000.Competition

~~Geology~~The ~~and~~competitive ~~Potential~~landscape ~~Silver~~primarily ~~Sources~~involves onthe company’s portfolio of development drugs, since the ~~Remington~~current ~~Claims~~commercial products have unique positions in their markets such that there are no true competitive medicines at this time. New competition for the development projects include potential intranasal preparations of naloxone, for example developed by AntiOp Inc and intramuscular injection versions, for example Evzio developed by Kaleo Inc, over which we believe we have competitive advantage.

~~Rocks in~~We ~~the~~understand ~~Remington~~intranasal ~~lode~~preparations ~~claims~~can ~~area~~have ~~consist~~problems of apracticality ~~package of Jurassic-age sedimentary rocks of the Dunlap Formation~~ and ~~Triassic-age Gabbs~~effectiveness ~~and~~whereas ~~Sunrise~~intramuscular ~~Formations.~~injection ~~The~~is ~~Dunlap~~a ~~Formation consists of interstratified sandstones, conglomerate and volcanic flows and~~proven ~~tuffaceous sandstones. The Gabbs~~ and ~~Sunrise~~easy ~~Formations~~method ~~sandstones consist~~ of ~~limey sandstone, sandy limestone and siltstone, with occasional interbeds of shale~~application. ~~These~~We ~~rock~~believe ~~types~~the ~~generally~~development ~~make~~model ~~good~~we ~~host~~use ~~rocks~~can ~~for~~get ~~mineralization.~~ALT022 ~~Bedding~~to ~~generally~~market ~~strikes northwest~~quickly and ~~parallels~~efficiently. ~~the ridgeline~~Furthermore, an ~~and~~intranasal ~~dips~~preparation toof ~~the~~midazolam ~~southwest. The contact between the Triassic and Jurassic rocks~~ is ~~noted~~ in ~~the~~development ~~literature~~(Upsher asSmith anInc) ~~unconformity,~~which ~~however,~~could ~~here~~compete itwith ~~is likely faulted~~ALT025. ~~The~~ ~~thickness~~Current ~~of the sedimentary package is not~~competition ~~well~~to ~~understood~~these atprojects ~~this time but~~ is ~~believed~~in ~~to be on~~ the ~~order~~form of ageneric ~~few~~ampoules/vials ~~thousand feet or more. Tectonic disruption~~ of ~~the~~these ~~sediment units~~medicines iswhich ~~common.~~whilst ~~Folding~~inexpensive, ~~is both local and regional. Drag folds associated regional folding~~ are ~~often~~not ~~sheared~~suited ~~and~~to ~~smallscale anticlinal~~SOS ~~folding~~situations ~~forms~~in ~~wide separations between varying rock compositions. Although no large-scale faults were seen on~~ the ~~Remington~~community ~~lode claim~~due ~~block, a short distance away and~~ to the ~~south~~increased isrisk ~~a large normal fault that brings sedimentary rocks adjacent~~ to ~~the~~both ~~Tertiary volcanic~~patient ~~rocks~~and ~~that cap much of the Garfield Hills~~caregiver.

~~Rocks of~~Government ~~the~~Approval Garfield Hills show strong alteration halos that suggest plutonic intrusion at relatively shallow depths. The general circular topographic shape of the Garfield Hills suggests that it sits on top of a collapsed plutonic dome. Basaltic-andesitic dikes are scattered on the Remington claims. These intrusions were likely the driving sources for the alterations and ~~mineralizations.~~Regulation

~~Alterations~~The ~~generally~~research, ~~consisted~~pre-clinical ofdevelopment, ~~either:~~clinical ~~(1)~~trials, aproduct ~~weak~~manufacturing toand ~~strong~~marketing ~~iron~~which ~~oxide~~may ~~veining~~be ~~that~~conducted by us is ~~accompanied~~subject to regulation by ~~some~~the ~~quartz~~FDA ~~veining~~ and ~~some~~similar ~~argillicization, or~~health ~~(2)~~authorities ~~multiple-phase~~in ~~quartz~~foreign ~~veining~~countries. ~~with~~Our ~~visible~~proposed ~~precious~~products and ~~base~~technologies ~~metal~~also ~~mineralization.~~may be ~~The~~subject ~~iron~~to ~~oxide~~certain ~~alteration~~other ~~occurs~~federal, ~~in broad~~state ~~aureoles~~and ~~about~~local ~~the~~government ~~property.~~regulations, ~~They~~including, ~~seem~~without tolimitation, bethe ~~following~~Federal ~~zones~~Food, Drug ofand ~~structural~~Cosmetic ~~weakness~~Act, ~~developed~~and bytheir ~~either~~state, ~~the~~local ~~folding~~and orforeign ~~faulting~~counterparts. ~~Some~~ ~~iron~~Although ~~oxide~~there ~~alteration~~can isbe ~~intense~~no tosuch aassurance, ~~point~~we ofdo ~~becoming~~not ~~gossen-like.~~believe that ~~The~~compliance ~~iron~~with ~~oxides~~such ~~alterations~~laws ~~are~~and ~~impregnated~~regulations ~~with~~has, ~~thin brown~~nor tois ~~druzy~~presently ~~quartz~~expected ~~veinlets~~to ~~and~~have, ~~remnant~~a ~~iron~~material ~~sulfides~~adverse ~~can~~effect beon ~~seen~~our ~~trapped~~business. However, ~~within~~we ~~the~~cannot ~~siliceous~~predict ~~matrix.~~the ~~Several~~extent ~~large~~of ~~siliceous iron~~the ~~oxide~~adverse ~~alteration~~effect ~~haloes~~on ~~were~~its ~~observed~~business onor the ~~claims~~financial ~~but~~and ~~had~~other nocost ~~prospect~~that ~~pits.~~might ~~Samples~~result from ~~RC-1~~any ~~and~~government ~~RC-2~~regulations ~~were~~arising ~~obtained~~out ~~from~~of ~~these perimeter~~future ~~alterations~~legislative, administrative or judicial action.

~~The quartz~~Generally, ~~veining~~the ~~mineralization~~steps ~~associated~~required ~~with~~before ~~the~~a ~~oxide~~pharmaceutical ~~alteration~~or istherapeutic ~~predominantly~~biological ~~milky~~agent ~~white~~may ~~and~~be ~~often~~marketed ~~shows~~in ~~several~~the ~~phases~~United ofStates ~~brecciatation and~~include: ~~remineralization.~~(i) ~~Boiling~~pre-clinical laboratory oftests, ~~the~~in ~~siliceous~~vivo ~~solutions~~pre-clinical isstudies ~~prevalent~~in animals, ~~leaving~~toxicity ~~behind~~studies ~~vugs~~ and ~~corroded~~formulation ~~minerals,~~studies; ~~giving~~(ii) the ~~rocks a~~submission ~~sugary~~to ~~texture~~the FDA ~~with~~of ~~dirty~~an ~~brown~~IND toapplication ~~gray-black~~for ~~appearance~~human ~~from~~clinical ~~the silver~~testing, ~~lead~~that ~~and~~must ~~zinc~~become ~~minerals.~~effective ~~Observed~~before ~~ore~~human ~~minerals~~clinical ~~were argentite,~~trials ~~acanthite.~~commence; ~~cerussite,~~(iii) adequate ~~galena,~~and ~~malachite,~~well-controlled ~~azurite,~~human ~~smithsonite~~clinical ~~and~~trials ~~chalcosite.~~to ~~The~~establish ~~argentite~~the safety and ~~acanthite~~efficacy ~~showed evidence~~ of ~~being~~the ~~leached~~drug; ~~and,~~(iv) ~~therefore,~~the ~~silver~~submission ~~assay~~of ~~values~~a marketing ~~are~~application ~~expected~~to bethe ~~lower~~FDA; atand ~~the~~(v) ~~surface~~FDA ~~and~~approval ~~should~~of ~~increase~~the ~~with~~marketing ~~depth.~~application ~~Inch-wide veins~~prior ofto ~~galena~~any ~~were~~commercial ~~observed.~~sale ~~Calcite,~~or ~~barite,~~shipment ~~hematite,~~of the ~~magnetite,~~drug. ~~adularia~~We, ~~siderite~~through ~~and~~our andevelopment ~~assemblage~~strategy, ofwill ~~clay~~not ~~minerals~~be ~~are among~~required ~~the~~to ~~gangue~~undertake ~~minerals.~~pre-clinical ~~While~~studies ~~most~~in ofanimals, ~~the~~toxicity ~~veins~~studies or ~~are~~clinical ~~less~~efficacy ~~than~~trials ~~six~~making ~~inches~~our ~~wide,~~process ~~some~~theoretically ~~are~~quicker ~~over~~and ~~three~~less ~~feet wide~~expensive.

Every clinical trial must be conducted under the review and oversight of an institutional review board (IRB) at each institution participating in the trial. The IRB evaluates, among other things, ethical factors, the safety of human subjects, and the possible liability of the institution.

Clinical trials are typically conducted in three sequential phases, although the phases may overlap. Phase I represents the initial introduction of the drug to a small group of healthy subjects to test for safety, dosage tolerance, and the essential characteristics of the drug. Phase II involves studies in a limited number of patients to test the safety and efficacy of the drug at different dosages. Phase III trials involve large-scale evaluation of safety and effectiveness, usually (though not necessarily) in comparison with placebo or an existing treatment. Again, the Company does not anticipate having to conduct Phase III studies for its lead development candidates.

The results of the pre-clinical and clinical trials are submitted to the FDA as part of an application to market the drug. The marketing application also includes information pertaining to the chemistry, formulation, manufacture of the drug and each component of the final product. The FDA review of a marketing application takes from one to two years on average to complete, though reviews of treatments for cancer and other life-threatening diseases may be accelerated. However, the process may take substantially longer if the FDA has questions or concerns about a product. Following review, the FDA may ultimately decide that an application does not satisfy regulatory and statutory criteria for approval. In some cases, the FDA may approve a product but require additional clinical tests following approval (i.e., Phase IV).

Table of Contents

~~Competition~~In addition to obtaining FDA approval for each product, each domestic drug manufacturing establishment must be registered with, and approved by, the FDA. Domestic manufacturing establishments are subject to inspections by the FDA and must comply with Good Manufacturing Practice ("GMP"). To supply products for use in the United States, foreign manufacturing establishments must comply with GMP and are subject to periodic inspection by the FDA or by corresponding regulatory agencies in such countries under reciprocal agreements with the FDA.

~~The mineral~~If ~~exploration~~marketing ~~industry~~approval of any product is granted, inwe ~~general~~must continue to comply with FDA requirements not only for manufacturing, isbut also ~~intensely~~for ~~competitive~~labeling, advertising, record keeping, and ~~even~~reporting ifto ~~commercial~~the ~~quantities~~FDA of ~~reserves~~adverse ~~are~~experiences ~~discovered~~and other information. In addition, we amust ~~ready~~comply with federal and state health care anti-kickback laws and other health care fraud and abuse laws that affect the ~~market~~marketing ~~may~~of pharmaceuticals. Failure to comply with applicable laws and regulations could subject us to administrative or judicial enforcement actions, including but not ~~exist~~limited ~~for~~to ~~the~~product ~~sale~~seizures, injunctions, civil penalties, criminal prosecution, refusals to approve new products and/or withdrawal of existing approvals, as well as increased product liability exposure, any of which could have a material adverse effect on the ~~reserves~~company's business, financial condition, or results of operations.

~~Most companies~~For ~~operating~~clinical ininvestigation ~~this~~and ~~industry~~marketing outside the United States, we are ~~more~~also ~~established~~subject to foreign regulatory requirements governing human clinical trials and ~~have~~marketing ~~greater~~approval ~~resources~~for todrugs. ~~engage~~The inrequirements governing the ~~production~~conduct of ~~mineral~~clinical ~~claims. We~~trials, product licensing, ~~were~~pricing ~~incorporated~~and onreimbursement ~~July~~vary ~~15,~~widely ~~2011~~for European countries both within and ~~our~~outside ~~operations~~the ~~are~~European ~~not~~Community ~~well-established~~("EU"). ~~Our~~ Outside ~~resources~~the atUnited ~~the~~States, ~~present~~our ~~time~~ability ~~are~~to market a product is contingent upon receiving a marketing authorization from the appropriate ~~limited~~regulatory authority. We ~~may~~At ~~exhaust~~present, ~~all~~foreign ofmarketing ~~our~~authorizations ~~resources~~are ~~and~~applied befor ~~unable~~at toa ~~complete~~national ~~full~~level, ~~exploration~~although ofwithin the ~~Remington mineral claims. There~~EU iscertain ~~also~~registration ~~significant~~procedures ~~competition~~are available to ~~retain~~companies ~~qualified~~wishing ~~personnel~~ to ~~assist~~market their products in ~~conducting~~more ~~mineral~~than ~~exploration~~one ~~activities~~EU member state. If aIf ~~commercially~~the ~~viable~~regulatory ~~deposit~~authority is ~~found~~satisfied tothat ~~exist~~adequate ~~and~~evidence weof ~~are~~safety, ~~unable~~quality toand ~~retain~~efficacy ~~additional~~has ~~qualified~~been ~~personnel~~presented, wea ~~may~~marketing authorization will be ~~unable~~granted. toThe system for obtaining marketing authorizations within the EU registration system is a dual one ~~enter~~in ~~into~~which ~~production~~certain products, such as biotechnology and ~~achieve~~high ~~profitable~~technology ~~operations. These~~products ~~factors~~and ~~set~~those ~~forth~~containing ~~above~~new ~~could~~active ~~inhibit~~substances, ~~our~~will have ~~ability~~access to ~~compete~~ ~~with~~a ~~other~~central ~~companies~~regulatory insystem that provides registration throughout the ~~industry~~entire ~~and~~EU. ~~entered~~Other ~~into~~products ~~production~~will be registered by national authorities in individual EU member states, operating on a principle of mutual recognition. This foreign regulatory approval process includes, at least, all of the ~~mineral~~risks ~~claim~~associated ifwith aFDA ~~commercial~~approval ~~viable~~set ~~deposit~~forth isabove. We could possibly have greater ~~found~~difficulty in obtaining any such approvals and also might find it more difficult to ~~exist~~protect our intellectual property abroad.

Numerous factors beyond our control may affect the marketability of any substances discovered. These factors include market fluctuations, the proximity and capacity of natural resource markets and processing equipment, government regulations, including regulations relating to prices, taxes, royalties, land tenure, land use, importing and exporting of minerals and environmental protection. The exact effect of these factors cannot be accurately predicted, but the combination of these factors may result our not receiving an adequate return on invested capital.

Compliance with Government Regulation

The General Mining Law of May 10, 1872, as amended (30 U.S.C. §§ 22-54 and §§ 611-615) is the major U.S. federal law governing locatable minerals. This law allows citizens of the United States the opportunity to explore for, discover, and purchase certain valuable mineral deposits on those federal lands that are open to mineral entry. The law sets general standards and guidelines for claiming the possessory right to a valuable mineral deposit discovered during exploration. The General Mining Law allows for the enactment of state laws governing location and recording of mining claims and sites that are consistent with federal law. The federal regulations implementing the General Mining Law are found at Title 43 of the Code of Federal Regulations (CFR) in Groups 3700 and 3800.

A mining claim is a selected parcel of U.S. federal land, valuable for a specific mineral deposit or deposits, for which the claimant has asserted a right of possession under the General Mining Law. Our rights to the Remington claims are restricted to the exploration and extraction of a mineral deposit. The rights granted by a mining claim protect against a challenge by the United States and other claimants only after the discovery of a valuable mineral deposit. The two types of mining claims are lode and placer. The Remington claim is a lode claim. Lode Claims cover classic veins or lodes having well-defined boundaries and also include other rock in-place bearing valuable mineral deposits. Lode claims are usually located as parallelograms with the side lines parallel to the vein or lode. The end lines of the lode claim must be parallel to qualify for underground extralateral rights. Extralateral rights involve the rights to minerals in vein or lode form that extend at depth outside the vertical boundaries of the claim. The Remington claims are unpatented mining claims. A patented mining claim is one for which the federal government has conveyed title, making it private land. Since October 1, 1994, the BLM has been prohibited by acts of Congress from accepting any new mineral patent applications.

Generally, all claimants must pay an annual maintenance fee per claim or site to the BLM, or file for a waiver from payment of fees by September 1 of each year. Failure to file for a waiver or pay the fee by September 1 results in the claim or site becoming forfeited by operation of law. Claimants having an interest in 10 or fewer claims nationwide may elect to file for a waiver from payment of the maintenance fee and perform annual labor or make improvements worth $100 each year for each mining claim held. Assessment work is work or labor that performed that develops the claim for production (43 CFR Part 3836). Geological, geophysical, and geochemical surveys may qualify as assessment work for a limited period. Use of these surveys requires the filing of a detailed report, including basic findings.

State laws also require the annual filing of an affidavit of assessment work with the proper county if the work is performed. The filing of an affidavit of annual assessment work with both the local county office and the proper BLM State Office is required if the claimant elects to file a waiver from payment of the maintenance fees. The affidavit or proof of labor must be filed no later than December 30 following the filing of a waiver in the proper BLM State Office and in the county or borough recorder’s office.

Table of Contents

Performance of assessment work must be within a certain period referred to as the assessment year. The assessment year begins at noon of each September 1. It ends at noon September 1 of the next year (43 CFR Part 3836). Performance of assessment work need not occur during the first assessment year of location.

Exploration and mining activities on BLM-administered land are controlled by the regulations of the Secretary of the Interior contained in 43 CFR, Subparts 3715 and 3809. We are required by these regulations to prevent unnecessary or undue degradation of the land. For activities other than casual use, we will be required to submit either a notice or a plan of operations. A plan of operations, which includes a reclamation plan, is required where activities involve the surface disturbance of more than 5 acres. Notices also require the submission of a reclamation plan and are submitted for exploration activities covering 5 acres or less. There is no requirement for notifying the BLM of casual use activities. Casual use activities are those that cause only negligible disturbance of public lands and resources. For example, activities that do not involve the use of earthmoving equipment or explosives may be considered casual use.

We will be required to reclaim any surface disturbing activity, even if the claim or site is declared abandoned and void or forfeited by the BLM. Reclamation will be required if we relinquish the claim or site to the Federal Government. The BLM requires a reclamation bond or other financial security prior to approving a plan of operations or allowing operations under a notice to proceed. Surface Management actions are processed at the local level. The relevant BLM district office for the Remington claims is in Carson City, Nevada.

Although we do not believe that our currently planned sampling and related exploration activities will require permitting from the BLM, we do intend to begin the permitting process for subsurface mineral sampling through exploration test pits or through dozer cuts. We intend to submit a plan of operations for these activities to the BLM district office with the assistance of our consulting geologist. The plan of operations must include appropriate environmental protection and reclamation measures and describe either the entire operation proposed or reasonably foreseeable operations and how they would be conducted, including the nature and location of proposed structures and facilities.

The public has the conditional right to cross mining claims or sites for recreational and other purposes and to access federal lands beyond the claim boundaries. Although claimants have a right of access to a mining claim or site across federal lands, they are not allowed to cause unnecessary or undue degradation of the surface resources. Claimants may be liable for damages if found responsible for unnecessary loss of or injury to property of the United States. We may not construct permanent structures, mobile structures, or store equipment without the prior approval of an authorized federal official.

Employees

We ~~have~~ nohave ~~employees~~five ~~other~~full-time ~~than our president and CEO, Mr. Scoggins. We conduct our business largely through agreements with consultants and other independent third party vendors.~~employees:

~~Research and~~Michael ~~Development~~Hawthorne ~~Expenditures~~Chief Executive Officer, President & Director Vinod Kaushal Executive Chairman & Director Lorna Peers Chief Financial Officer, Treasurer, Secretary & Director Lynsay Nixon Manufacturing Manager Eleanor Pow Commercial Coordinator

We have not incurred any research or development expenditures since our incorporation.

Subsidiaries

We do not currently have any subsidiaries.

Patents and Trademarks

We do not own, either legally or beneficially, any patent or trademark.

Table of Contents

Item 2. Properties

~~The Remington~~We #1lease -premises 4both ~~claims~~in ~~consists~~Scotland, ofUK ~~four~~and ~~contiguous~~Palo ~~unpatented~~Alto, ~~lode~~California. ~~mining~~The ~~claims~~premises ~~covering~~in ~~approximately~~Scotland ~~100~~are ~~acres~~leased infrom ~~Township~~Biocity 6Scotland ~~North,~~Limited. ~~Range~~The 32lease ~~East~~has (Ta ~~6N,~~three Rmonth ~~32E),~~break ~~section~~notice 7,period and ~~Township~~the 6term ~~North,~~of ~~Range~~the 33lease ~~East~~ends (Ton ~~6N,~~November ~~R 33E)~~30, ~~Sections~~2018 8but ~~and~~can ~~17,~~be ~~Mount~~continued ~~Diablo~~by ~~Base~~mutual ~~and Meridian (MDB&M)~~consent. The ~~claims~~premises ~~are~~leased ~~identified~~consist asof ~~Bureau~~4 ofrooms; ~~Land~~2 ~~Management~~laboratory ~~Nevada~~areas ~~Mining~~and ~~Claim~~2 ~~Nos~~office areas. ~~NMC~~Rent ~~1035534,~~and ~~NMC~~service ~~1035535, NMC~~charge ~~1035536,~~is ~~and~~payable ~~NMC~~monthly in ~~1035537,~~advance ~~respectively,~~at ~~and~~a ~~total~~rate ~~roughly~~of ~~100~~$9,610 ~~acres~~per ~~in size~~month.

~~Figure~~The 1,premises ~~below,~~in ~~shows~~Palo ~~the~~Alto ~~location~~are ofleased ~~the~~from ~~Property~~Regus ~~and~~with ~~the~~rent ~~means~~payable ofin ~~access~~advance toat ~~the~~a ~~property~~rate inof ~~Mineral~~$299 ~~County,~~per ~~Nevada~~month.

Table of Contents

Figure 2, below, shows the boundaries of the Remmington claim block and the elevations on and around the property.

Item 3. Legal Proceedings

We are not ~~currently~~ a party to any pending legal ~~proceedings~~proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Our agent for service of process in Nevada is Gary A. Scoggins, 7582 Las Vegas Blvd. S., Ste 236, Las Vegas, NV 89123.

Item 4. Mine Safety Disclosures

~~Not applicable.~~N/A

Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock is ~~currently~~ quoted under the symbol “ATOA” on the ~~OTC~~OTCBB ~~Bulletin~~operated ~~Board~~by the Financial Industry Regulatory Authority, Inc. (“~~OTCBB~~FINRA”), ~~which~~and isthe ~~sponsored~~OTCQB operated by ~~FINRA.~~OTC ~~The~~Markets ~~OTCBB~~Group, isInc. Few ~~a network~~market ofmakers ~~security~~continue ~~dealers~~to ~~who~~participate ~~buy~~in the ~~and~~OTCBB ~~sell~~system ~~stock.~~because ~~The~~of ~~dealers~~high ~~are~~fees ~~connected~~charged by aFINRA. Consequently, ~~computer~~market ~~network~~makers that ~~provides~~once ~~information~~ quoted our shares on ~~current~~the ~~"bids"~~OTCBB system ~~and~~may ~~"asks",~~no aslonger ~~well~~be asposting ~~volume~~a ~~information~~quotation for our shares. ~~Our~~As of the date of this report, however, our shares are quoted by several market makers on the ~~OTCBB~~OTCQB. ~~under~~The criteria for listing on either the OTCBB or OTCQB are similar and include that we remain current ~~symbol~~in ~~“RMMG”~~our SEC reporting. Our reporting is presently current and, since inception, we have filed our SEC reports on time.

~~The~~Only ~~following~~a ~~table~~limited ~~sets~~market ~~forth~~exists ~~the~~for ~~range~~our ofsecurities. ~~high~~There ~~and~~is ~~low~~no ~~bid~~assurance ~~quotations~~that ~~for~~a ~~our~~regular ~~common~~trading ~~stock~~market ~~for~~will ~~each~~develop, ofor ~~the~~if ~~periods indicated as~~developed, ~~reported~~that byit ~~the~~will ~~OTCBB~~be sustained. ~~These quotations reflect inter-dealer prices~~Therefore, ~~without~~a ~~retail~~shareholder ~~mark-up,~~may ~~mark-down~~be orunable ~~commission~~to ~~and~~resell ~~may~~his ~~not necessarily~~securities ~~represent~~in ~~actual~~our ~~transactions~~company.

Fiscal Year Ending July 31, 2013
Quarter Ended		High $		Low $
	July 31, 2013	$	0.20	$	0.20
	April 30, 2013	$	0.20	$	0.20
	January 31, 2013	$	0.20	$	0.20
	October 31, 2012	$	0.20	$	0.20
Fiscal Year Ending July 31, 2012
	Quarter Ended		High $		Low $
	July 31, 2012	$	0.20	$	0.20
	April 30, 2012		n/a		n/a
	January 31, 2012		n/a		n/a
	October 31, 2011		n/a		n/a

The following table sets forth the range of high and low bid quotations for our common stock for each of the periods indicated as reported by the OTCQB. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

Fiscal Year Ending July 31, 2014
Quarter Ended		High $		Low $
	July 31, 2014		5.00		0.16
	April 30, 2014		4.00		0.51
	January 31, 2014		—		—
	October 31, 2013		—		—

Fiscal Year Ending July 31, 2013
Quarter Ended		High $		Low $
	July 31, 2013		0.20		0.20
	April 30, 2013		0.20		0.20
	January 31, 2013		0.20		0.20
	October 31, 2012		0.20		0.20

On October 8, 2014, the last sales price per share of our common stock on the OTCQB was $0.45.

Penny Stock

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

The ~~broker-dealer~~penny ~~also~~stock ~~must~~rules ~~provide~~require a broker-dealer, prior to ~~effecting~~a ~~any~~ transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the ~~customer~~SEC, ~~with~~that: (a) ~~bid~~contains a description of the nature and ~~offer~~level ~~quotations for~~of risk in the market for penny ~~stock~~stocks in both public offerings and secondary trading; (b) ~~the~~contains ~~compensation~~a description of the broker-’s or dealer’s duties to the customer and ~~its~~of ~~salesperson~~the inrights and remedies available to the ~~transaction~~customer with respect to a violation of such duties or other requirements of the securities laws; (c) ~~the~~contains ~~number~~a brief, clear, narrative description of ~~shares to~~a ~~which~~dealer ~~such~~market, including bid and ask prices ~~apply,~~for penny orstocks ~~other~~and ~~comparable~~the ~~information~~significance ~~relating~~of tothe spread between the ~~depth~~bid and ~~liquidity~~ask ofprice; ~~the~~(d) ~~market~~contains a toll-free telephone number for inquiries ~~such~~on ~~stock~~disciplinary actions; ~~and~~ (de) adefines ~~monthly~~significant ~~account~~terms ~~statement~~in ~~showing~~ the ~~market~~disclosure ~~value~~document or in the conduct of ~~each~~trading in penny ~~stock~~stocks; and ~~held~~(f) contains such other information and is in such form, including language, type size and format, as the ~~customer's~~SEC ~~account~~shall require by rule or regulation.

10The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer’s account.

Table of Contents

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser'’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions ~~involving~~ involving penny stocks, and a signed and dated copy of a written suitability statement.

These disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have difficulty selling our securities.

Holders of Our Common Stock

As of October ~~28,~~22 ~~2013~~2014, we had 1377,~~000~~650,~~000~~166 shares of our common stock issued and outstanding, held by ~~thirty-one~~five (315) shareholders of record, with others holding shares in street name.

Dividends

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:

1.	we would not be able to pay our debts as they become due in the usual course of business, or;
2.	our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

1. we would not be able to pay our debts as they become due in the usual course of business, or;

2. our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

Recent Sales of Unregistered Securities

We closed an issue of 10,000,000 shares of common stock on July 19, 2011 to Gary A. Scoggins, our president, CEO, CFO, and sole director. Mr. Scoggins acquired these shares in exchange for $30,000 at a price of $0.003 per share. These shares were issued pursuant to Section 4(2) of the Securities Act of 1933 and are restricted shares as defined in the Securities Act. We did not engage in any general solicitation or advertising.

Securities Authorized for Issuance under Equity Compensation Plans

~~None~~We do not have any equity compensation plans.

Recent Sales of Unregistered Securities

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

On January 15, 2014, we issued 2,050,000 shares of our common stock in exchange for a subscription receivable in the amount of $2,050.

On May 2, 2014, we an investor 69,833 common shares at a price of $6 per share, for a total proceeds of $419,000. As of July 31, 2014 the shares were unissued.

On June 20, 2014, we issued 37,325,083 shares to our CEO, Michael Richard Hawthorne, and 37,325,083 to our Executive Chairman, Vinod Kaushal at $0.001 per share.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 6. Selected Financial Data

A smaller reporting company is not required to provide the information required by this Item.

118

Table of Contents

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse ~~affect~~effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

~~Management’s Discussion~~Results ~~and~~of ~~Analysis~~Operations offor ~~Financial~~period ~~Condition~~from ~~and~~November 22, ~~Results~~2013 of(inception) ~~Operations~~to July 31, 2014

Our business plan is to proceed with the exploration of the Remmington mineral claims to determine whether there are commercially exploitable reserves of silver. We intend to proceed with the additional exploration program as recommended by our consulting geologist.Revenues

~~Based on~~We ~~the~~had ~~results~~revenues of $64,913 for the ~~initial~~period ~~Phase~~from November 122, ~~reconnaissance~~2013 ~~sampling~~(inception) ~~program~~to July 31, 2014. Our revenues have shown month on month growth since inception. We anticipate revenue will continue to grow, however, we are a development stage company and there is no guarantee that we will be able to successfully execute our ~~consulting~~business ~~geologist~~plan. ~~has~~Gross ~~recommended~~profit ~~undertaking~~for ~~additional~~the period from November 22, 2013 (inception to July 31, 2014 was $17,445, or 26.87% ~~exploration~~of ~~activities~~revenues.

~~Our planned~~Operating ~~additional exploration activities are as follows:~~Expenses

~~Planned~~Operating ~~Exploration~~expenses ~~Activities~~were -$801,064 ~~Sampling~~for ~~and assaying of additional prospects observed around~~ the ~~boundaries~~period from ofNovember ~~the Remmington claim block~~22, ~~with~~2013 ~~acquisition~~(inception) ~~through~~to ~~additional~~July ~~claim~~31, ~~staking if positive results are returned~~2014. -These ~~Conduct~~consisted ~~vicinity~~of salaries and ~~detailed~~wages ~~local~~of ~~geological~~$298,346, ~~mapping~~professional -fees ~~Conduct~~of a$255,289, rent ~~detailed~~expenses ~~rock~~of ~~sampling~~$125,392, ~~program~~general onand ~~the~~administrative ~~Remmington~~expenses ~~claims~~of ~~with~~$89,053 ~~between~~and ~~100-200~~research ~~samples~~and -development ~~Begin~~of ~~the permitting process for subsurface mineral sampling through exploration test pits or through dozer cuts~~$32,984.

~~Our planned~~We ~~additional~~anticipate ~~exploration~~our ~~activities~~operating ~~are~~expenses ~~expected~~will toincrease as ~~cost~~we ~~approximately~~undertake ~~$20,000~~our plan of operations. We ~~will~~The ~~require~~increase ~~some~~will ~~additional~~be ~~capital~~ attributable to ~~fully~~development, ~~fund~~administrative ~~our~~and ~~additional~~operating ~~planned~~costs ~~exploration~~associated with ~~activities~~our asplanned ~~outlined~~activities ~~above. Sampling~~ and ~~other~~the ~~data~~professional ~~acquired~~fees ~~during~~associated with our ~~exploration~~ reporting obligations under the Securities Exchange Act of ~~Remmington~~1934. ~~claims~~We ~~will~~intend ~~ultimately~~to ~~determine~~closely ~~whether~~monitor ~~the~~and ~~project~~align ~~will~~our ~~become~~operating ~~economically~~costs ~~viable~~to our anticipated revenue growth.

~~Results of~~Net ~~Operations for the Years Ended July 31, 2013 and 2012, and for the period from July 15, 2011 (date of inception) through July 31, 2013~~Loss

We ~~have~~ ~~not earned any revenues since the inception of our current business operations. We~~ incurred ~~expenses and~~ a net loss ~~in the amount~~ of $79773,~~978~~522 for the period ~~year~~from ~~ended~~November ~~July 31~~22, 2013. Our expenses consisted of professional fees in the amount of $78,412, exploration costs of $606, and general and administrative expenses in the amount of $960. By comparison, we incurred expenses and a net loss in the amount of $71,153 for the year ended July 31, 2012. Our expenses consisted of professional fees in the amount of $68,650, exploration costs of $560, and general and administrative expenses in the amount of $1,943. We have incurred total expenses and a net loss of $159,410 from (inception) onto July ~~15, 2011 through July~~ 31, ~~2013~~2014.

Table of Contents

Liquidity and Capital Resources

~~As of~~We ~~July 31 2013, we~~ had current assets ~~in the amount~~ of $~~811~~365,408 ~~consisting~~as ~~entirely~~ of ~~cash~~July 31, 2014. ~~Our~~We had current liabilities as of ~~July 31, 2013, were~~ $~~127~~344,~~621,~~995 ~~consisting~~as ~~entirely~~ of ~~accounts~~July ~~payable~~31, ~~and accrued expenses~~2014. ~~Thus,~~We wetherefore had a working capital ~~deficit~~ of $~~126~~20,~~810~~ 413 as of July 31, ~~2013~~ 2014.

~~We have~~Operating ~~incurred~~activities ~~cumulative~~used ~~net losses of~~ $~~159~~657,~~410~~111 ~~since~~in ~~inception. We have not attained profitable operations and are dependent~~cash ~~upon~~for ~~obtaining~~the ~~financing~~period infrom ~~order~~November ~~to continue pursuing significant exploration activities. As discussed above~~22, we2013 ~~have~~(inception) ~~completed Phase I of our exploration program and intend~~ to goJuly ~~forward with Phase II at an approximate cost of $20~~31,~~000~~ 2014. Our ~~cash~~negative onoperating ~~hand will~~cash ~~not~~flow befor ~~sufficient to fund~~ the ~~full~~period ~~recommended~~was ~~Phase II exploration program together with our ongoing administrative expenses.~~mainly ~~Additional financing will therefore be required in order for us to proceed with Phase II. At this time, we do not have any financing commitments or other arrangements in place. We therefore face~~ a ~~significant~~result ~~risk that we will be unable to complete the entirety~~ of our ~~planned~~net ~~exploration~~loss ~~program.~~for In the event that additional equity or debt financing cannot be obtained, we may consider performing a more limited Phase II exploration program in order to meet the constraints posed by our available capital resourcesperiod.

~~Off~~Investing activities for the period from November ~~Balance~~22, ~~Sheet~~2013 ~~Arrangements~~(inception) to July 31, 2014 used $20,490 for the purchase of fixed assets.

AsFinancing activities for the period from November of22, 2013 (inception) to July 31, ~~2013~~2014 generated $888,000 ~~there~~in ~~were~~cash, noincluding ~~off~~$419,000 ~~balance~~as ~~sheet~~loan ~~arrangements~~proceeds, $419,000 from the sale of common stock and $50,000 from cash advances.

On May 2, 2014, we sold a promissory note in the principal amount of $419,000 (the “Note”). The Note accrue interest at the rate of 6% per annum and is due and payable on the earlier of (i) the fourth anniversary of the date of the Note, (ii) upon the occurrence of fundraising of at least $8,400,000, the sale of assets or change of control, or (iii) when, upon or after the occurrence of an event of default, such amounts are declared due and payable by the holder or made automatically due and payable in accordance with the terms of the Note. Also on May 2, 2014, we sold 69,833 shares of our common stock to an accredited investor at $6.00 per share for total proceeds of $419,000, these shares have yet to be issued.

The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Table of Contents

Going Concern

~~Our~~ The accompanying financial statements have been prepared ~~assuming~~on ~~that we will continue as~~ a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We ~~have~~had incurred cumulative losses of $159,410 since inception, expect to incur further losses in the development of our business and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a ~~going~~net ~~concern.~~(loss) ~~Management’s~~from ~~plans include continuing to finance~~ operations ~~through the private or public placement~~ of ~~debt~~$783,619 ~~and/or~~for ~~equity securities and~~ the ~~reduction~~period offrom ~~expenditures.~~November ~~However~~22, no2013 ~~assurance can be given at this time~~(inception) as to ~~whether~~July we31, ~~will~~2014 ~~be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability~~ and ~~classification~~had ofan ~~recorded~~accumulated ~~asset~~deficit ~~amounts or the amounts and classification~~ of ~~liabilities that might be necessary should we be unable to continue as a going concern~~$773,522.

These conditions give rise to doubt about our ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our continuation as a going concern is dependent upon its ability to obtain additional financing or sale of our common stock as may be required and ultimately to attain profitability.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. ~~Management~~We ~~does~~do not believe that any ~~of our~~ accounting policies currently fit this definition.

Recently Issued Accounting Pronouncements

WeOn doJune ~~not~~10, ~~expect~~2014, the ~~adoption~~Financial ofAccounting ~~recently~~Standards Board (FASB) issued a new accounting ~~pronouncements~~statement tothat ~~have~~reduces asome ~~significant~~of ~~impact~~disclosures and onreporting ~~our~~requirements ~~results~~for development stage companies. The change will be in effect for the interim and annual periods beginning after December 15, 2014. As of ~~operations~~such date, among other things development stage entities will no longer be required to report inception-to-date ~~financials~~information. ~~position~~We orhave ~~cash~~elected ~~flow~~early adoption of this pronouncement and will no longer being reporting inception-to-date information.

Off Balance Sheet Arrangements

As of July 31, 2014, there were no off balance sheet arrangements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 8. Financial Statements and Supplementary Data

Index to Financial Statements Required by Article 8 of Regulation S-X:

Audited Financial Statements:
Financial Statements:
F-1	~~Report~~Reports of Independent Registered Public Accounting ~~Firm~~Firms
F-2	Consolidated Balance ~~Sheets~~Sheet as of July 31, ~~2013 and 2012;~~2014
F-3	~~Statements~~Consolidated Statement of Operations for the ~~years ended July 31, 2013 and 2012 and for the~~ period from ~~July~~November 1522, ~~2011~~2013 (~~date of~~ inception) ~~through~~to July 31, ~~2013~~2014
F-4	Consolidated Statement of ~~Stockholders’~~Other ~~Equity~~Comprehensive (Loss) for the period from ~~July~~November 1522, ~~2011~~2013 (~~date of~~ inception) ~~through~~to July 31, ~~2013;~~2014
F-5	~~Statements~~Consolidated Statement of ~~Cash~~Stockholders’ ~~Flows for the years ended July 31, 2013 and 2012 and for the period from July 15, 2011~~ (~~date of inception~~Deficit) ~~through~~at July 31, ~~2013~~2014
F-6	~~Notes~~Consolidated Statement of Cash Flows for the period from November 22, 2013 (inception) to ~~Financial~~July ~~Statements~~31, 2014
F-7	Notes to Consolidated Financial Statements

1410

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of

~~We have audited the accompanying balance sheet of Remmington Enterprises~~Altovida, Inc. as of July 31, 2013, and the related statement of operations, 1 stockholders’ deficit, and cash flows for the year then ended. These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We have ~~conducted~~audited ~~our~~the ~~audit~~accompanying inconsolidated ~~accordance~~balance ~~with~~sheet ~~the standards~~ of ~~the~~Altovida, ~~Public Company Accounting Oversight Board (United States)~~Inc. ~~Those~~as ~~standards~~of ~~require~~July ~~that~~31, we2014 ~~plan~~ and ~~perform~~ the ~~audit~~related toconsolidated ~~obtain reasonable~~statements ~~assurance~~of ~~about~~operations, ~~whether~~stockholders’ ~~the~~deficit, ~~financial~~and ~~statements~~cash ~~are~~flows ~~free~~for ofperiod ~~material~~from ~~misstatement.~~November ~~An audit includes examining~~22, on2013 a(inception) ~~test~~to ~~basis~~July 31, ~~evidence~~ ~~supporting~~2014. ~~the amounts and disclosures in the~~ These financial statements. Anare ~~audit~~the ~~also~~responsibility ~~includes~~of ~~assessing~~ the ~~accounting~~Company’s ~~principles used and significant estimates made by~~ management,. asOur ~~well~~responsibility asis ~~evaluating~~to ~~the~~express ~~overall~~an ~~financial~~opinion ~~statement presentation. We believe~~on ~~that~~these ~~our~~financial ~~audit~~statements ~~provides~~based aon ~~reasonable basis for~~ our ~~opinion~~audits.

InWe conducted our ~~opinion,~~audit in accordance with the ~~financial~~standards ~~statements~~of ~~referred~~the toPublic ~~above~~Company ~~present~~Accounting Oversight Board (United States). Those standards ~~fairly,~~require inthat ~~all~~we ~~material~~plan ~~respects,~~and perform the audit to obtain reasonable assurance about whether the financial ~~position~~statements ofare ~~Remmington~~free ~~Enterprises,~~of ~~Inc~~material misstatements. asAn ofaudit ~~July~~includes 31examining, ~~2013,~~on ~~and~~a ~~the~~test ~~results~~basis, ~~of its~~evidence ~~operation~~supporting the amounts and ~~its~~disclosures ~~cash~~in ~~flows~~the ~~for~~financial statements, assessing the ~~year~~accounting ~~then~~principles ~~ended~~used ,and insignificant ~~conformity~~estimates ~~with~~made ~~accounting~~by ~~principles~~management, ~~generally~~as ~~accepted~~well inas evaluating the ~~United~~overall ~~States~~financial ofstatement ~~America~~presentation. We believe that our audits provide a reasonable basis for our opinion.

~~The~~In our ~~accompanying~~opinion, the financial statements ~~have~~referred ~~been~~to ~~prepared~~above ~~assuming that~~present ~~the~~fairly, ~~entity will continue as a going concern. As discussed~~ in ~~Note~~all 2material torespects, the financial ~~statements,~~positions ~~the~~of ~~entity~~Altovida, Inc. ~~has~~as ~~suffered~~of ~~recurring losses~~July ~~from~~31, ~~operations~~2014, and ~~has~~the aresults ~~net~~of ~~capital~~its ~~deficiency~~operations ~~that~~and ~~raises~~its ~~substantial~~cash ~~doubt~~flows ~~about~~for ~~its~~period ~~ability~~from toNovember ~~continue~~22, as2013 a(inception) ~~going~~through ~~concern.~~July ~~Management's~~31, ~~plans~~2014, in ~~regard~~conformity towith ~~these~~accounting ~~matters~~principles ~~are~~generally ~~also~~accepted ~~described~~ in ~~Note 2. The financial statements do not include any adjustments that might result from~~ the ~~outcome~~United States of ~~this uncertainty~~America.

~~/s/~~The accompanying Lfinancial statements have been prepared assuming the Company will continue as a going concern.L. ~~Bradford~~As &discussed in Note 2 to the financial statements, the Company has suffered losses from operations, ~~LLC~~which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~October~~/s/ L.L. 29Bradford &Company, ~~2013~~LLC

Las Vegas, Nevada

November 21, 2014

F-1

Table of Contents

Remmington Enterprises, Inc.
(An exploration stage Company)
Condensed Balance Sheets
	July 31,			July 31,
	2013			2012
ASSETS
Current assets
Cash	$	811		$	11,642
Total current assets		811			11,642
Other assets
Capitalized mining claims		20,600			20,600
Total other assets		20,600			20,600
Total assets	$	21,411		$	32,242
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
Current liabilities
Accounts payable and accrued expenses	$	127,621		$	58,474
Total current liabilities		127,621			58,474
Stockholders’ (deficit)
Preferred stock, $0.001 par value; 10,000,000 shares authorized,
None issued and outstanding at July 31, 2013 and 2012, respectively		—			—
Common stock, $0.001 par value; 90,000,000 shares authorized,
12,900,000 and 13,000,000 issued and outstanding at
July 31, 2013 and 2012, respectively		12,900			13,000
Additional paid-in capital		40,300			41,000
Stock subscription receivable		—			(800	)
Deficit accumulated during the exploration stage		(159,410	)		(79,432	)
Total stockholders’ (deficit)		(106,210	)		(26,232	)
Total liabilities and stockholders’ (deficit)	$	21,411		$	32,242

ALTOVIDA, INC.

~~The~~(Formerly ~~accompanying~~Remmington ~~notes~~Enterprises, ~~are an integral part of theses financial statements~~Inc.)

Consolidated Balance Sheet

	July 31,
	2014
ASSETS
Current assets:
Cash	$	210,399
Accounts receivable		44,508
Prepaid and deposits		3,381
Inventory		49,718
Other current assets		57,402
Total current assets		365,408
Fixed assets:
Equipment, net of accumulated depreciation of $353		20,141
Total assets	$	385,549
LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities	$	344,995
Total current liabilities		344,995
Long term liabilities:
Note payable		445,000
Total long-term liabilities		445,000
Total liabilities		789,995
Stockholders' (deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of July 31, 2014.		—
Common stock, $0.001 par value; 90,000,000 shares authorized; 89,930,166 issued and outstanding at July 31, 2014		89,930
Subscription receivable		(74,580	)
Additional paid in capital		364,684
Other comprehensive income		(10,958	)
Accumulated (deficit)		(773,522	)
Total stockholders' (deficit)		(404,446	)
Total liabilities and stockholders' deficit	$	385,549

The notes are an integral part to these consolidated financial statements.

F-2

Table of Contents

Remmington Enterprises, Inc.
(An exploration stage Company)
Condensed Statements of Operations
							July 15, 2011
	For the Year Ended			For the Year Ended			(Inception) to
	July 31, 2013			July 31, 2012			July 31, 2013
Revenue	$	-		$	-		$	-
Operating expenses:
Professional fees		78,412			68,650			150,311
Exploration costs		606			560			6,166
General and administrative		960			1,943			2,933
Total operating expenses		79,978			71,153			159,410
Loss from operating activities		(79,978	)		(71,153	)		(159,410	)
Provision for incomes taxes		—			—			—
Net loss	$	(79,978	)	$	(71,153	)	$	(159,410	)
Net loss per share – basic and fully diluted	$	(0.01	)	$	(0.01	)
Weighted average shares outstanding		13,000,000			11,881,918

ALTOVIDA, INC.

~~The~~(Formerly ~~accompanying~~Remmington ~~notes~~Enterprises, ~~are an integral part of theses financial statements~~Inc.)

Consolidated Statement of Operations

	November 22, 2013
	(Inception) to
	July 31, 2014
Revenue:
Sales income	$	64,913
Cost of sales		47,468
Gross profit		17,445
Operating expenses
General and administrative		89,053
Professional fees		255,289
Rent expense		125,392
Research and development		32,984
Salaries and wages		298,346
Total operating expenses		801,064
(Loss) from operations		(783,619	)
Other income (expense)
Interest expense		(6,268	)
Gain on forgiveness of debt		24,000
(Loss) on foreign currency transactions		(7,635	)
Total other income (expense)		10,097
Net loss	$	(773,522	)
Net loss per common share - Basic and diluted	$	(0.03	)
Weighted average shares outstanding - Basic and diluted		22,361,319

The notes are an integral part to these consolidated financial statements.

F-3

Table of Contents

~~Remmington Enterprises~~ ALTOVIDA, ~~Inc~~ INC.

(AnFormerly ~~exploration~~Remmington ~~stage~~Enterprises, ~~Company~~Inc.)

~~Statements~~Consolidated Statement of ~~Changes~~Other inComprehensive ~~Stockholders’~~ (~~Deficit~~Loss)

																	(Deficit)
	November 22, 2013
																	Accumulated
	(Inception) to
		Preferred Stock			Preferred Stock	Common stock			Common stock			Additional Paid-in			Subscriptions			During the Exploration			Total Stockholders’
	July 31, 2014
		Shares			Amount	Shares			Amount			Capital			Receivable			Stage			(Deficit)
Net (loss)	$	(773,522	)
Balance:
Cumulative translation adjustment:
July 15, 2011 (Inception)		—		$	—	—		$	—		$	—		$	—		$	—		$	—
Foreign currency translation		(10,958	)
Common stock issued		—			—
Total comprehensive (loss)	$	(784,480	)
for cash – Related party		—			—	10,000,000			10,000			20,000			—			—			30,000
Net loss, July 31, 2011		—			—	—			—			—			—			(8,279	)		(8,279	)
Balance, July 31, 2011		—			—	10,000,000			10,000			20,000			—			(8,279	)		21,721
Common stock issued
for cash and receivables		—			—	3,000,000			3,000			21,000			(800	)		—			23,200
Net loss, July 31, 2012		—			—	—			—			—			—			(71,153	)		(71,153	)
Balance, July 31, 2012		—			—	13,000,000			13,000			41,000			(800	)		(79,432	)		(26,232	)
Common stock
subscription cancelled		—			—	(100,000	)		(100	)		(700	)		800			—			—
Net loss, July 31, 2013		—			—	—			—			—			—			(79,978	)		(79,978	)
		—		$	—	12,900,000		$	12,900		$	40,300		$	—		$	(159,410	)	$	(106,210	)

The ~~accompanying~~ notes are an integral part ofto ~~theses~~these consolidated financial statements.

F-4

Table of Contents

~~Remmington Enterprises~~ ALTOVIDA, ~~Inc~~ INC.

(AnFormerly ~~exploration~~Remmington ~~stage~~Enterprises, ~~Company~~Inc.)

~~Condensed~~Consolidated ~~Statements~~Statement of ~~cash~~Stockholders' ~~flows~~(Deficit)

							July 15, 2011
							Additional			Subscription			Other						Total
	For the Year Ended			For the Year Ended			(Inception) to
	Common Shares						Paid-in			Payable /			Comprehensive			Accumulated			Stockholders'
	July 31,			July 31,			July 31,
	Shares			Amount			Capital			Receivable			(Loss)			Deficit			Deficit
	2013			2012			2013
Balance, November 22, 2013 (inception)		—		$	—		$	—		$	—		$	—		$	—		$	—
Cash flows from operating activities:
Shares issued for cash		12,280,000			12,280			(12,280	)		—			—			—			—
Net loss	$	(79,978	)	$	(71,153	)	$	(159,410	)
Recapitalization - reverse merger		3,000,000			3,000			(41,966	)		—			—			—			(38,966	)
Adjustments to reconcile net loss
Shares issued for cash		—			—			418,930			70			—			—			419,000
to net cash used in operating activities:
Shares issued for cash - related party		74,650,166			74,650			—			(74,650	)		—			—			—
Changes in operating assets and liabilities:
Cumulative translation adjustment		—			—			—			—			(10,958	)		—			(10,958	)
Accounts payable and accrued expenses		69,147			55,225			127,621
Net (loss)		—			—			—			—			—			(773,522	)		(773,522	)
Net cash (used) by operating activities		(10,831	)		(15,928	)		(31,789	)
Balance, July 31, 2014		89,930,166		$	89,930		$	364,684		$	(74,580	)	$	(10,958	)		(773,522	)		(404,446	)
Cash flows from investing activities:
Purchase of mining claims		—			—			(20,600	)
Net cash (used) in investing activities		—			—			(20,600	)
Cash flows from financing activities:
Proceeds from the sales of common stock – related party		—			—			30,000
Proceeds from the sales of common stock		—			23,200			23,200
Net cash provided by financing activities		—			23,200			53,200
Net increase (decrease) in cash		(10,831	)		7,272			811
Cash – beginning of period		11,642			4,370			—
Cash – end of period	$	811		$	11,642		$	811
Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—		$	—
Cash paid for taxes	$	—		$	—		$	—

The ~~accompanying~~ notes are an integral part ofto ~~theses~~these consolidated financial statements.

F-5

Table of Contents

~~Remmington Enterprises~~ ALTOVIDA, ~~Inc~~ INC.

(AnFormerly ~~exploration~~Remmington ~~stage~~Enterprises, ~~Company~~Inc.)

~~Notes~~Consolidated toStatement ~~Condensed~~of ~~Financial~~Cash ~~Statements~~Flows

Note 1 Organization and Summary of Significant Accounting Policies

	November 22, 2013
	(Inception) to
	July 31, 2014
Cash flows from operating activities
Net (loss)	$	(773,522	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		353
Gain on forgiveness of debt		(24,000	)
Loss on foreign currency transactions		7,635
Changes in operating assets and liabilities
(Increase) in accounts receivable		(44,508	)
(Increase) in inventory		(49,718	)
(Increase) in prepaid expenses		(3,381	)
(Increase) in other assets		(57,402	)
Increase in accounts payable and accrued liabilities		287,432
Net cash used in operating activities		(657,111	)
Cash flows from investing activities
Purchase of fixed assets		(20,490	)
Net cash provided by inventing activities		(20,490	)
Cash flows from financing activities
Proceeds from cash advances		50,000
Proceeds from loans payable		419,000
Proceeds from the sale of common stock		419,000
Net cash provided by financing activities		888,000
Net change in cash		210,399
Cash at beginning of period		—
Cash at end of period	$	210,399
		—
Supplemental cash flow Information:
Cash paid for interest	$	—
Cash paid for income taxes	$	—
Supplemental disclosure of non-cash investing and financing activities:
Accounts payable and accrued liabilities assumed through acquisition	$	45,915

~~(A)Nature~~The notes ofare ~~Operations~~an integral part to these consolidated financial statements.

Remmington Enterprises, Inc. (an exploration stage company) (the "Company") was incorporated under the laws of the State of Nevada on July 15, 2011. Remmington Enterprises, Inc. is a precious metal mineral acquisition, exploration and development company.

(B) Basis of Presentation

The Company is in the exploration stage in accordance with Accounting Standards Codification (“ASC”) Topic No. 915.

These financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America and include the have been consistently applied in the preparation of the financial statements on a going concern basis, which assumes the realization of assets and the discharge of liabilities in the normal course of operations for the foreseeable future.

The Company has adopted a July 31 year end.

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and expenses during the reported period. Actual results could differ from those estimates.

(D) Cash and Cash Equivalents

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At July 31, 2013 and 2012, the Company had no cash equivalents.

(E) Exploration and Development Costs

In general, exploration costs are expensed as incurred. When the Company has determined that a mineral property can be economically developed as a result of establishing proven and probable reserves, the costs incurred to develop such property are capitalized. Costs incurred to maintain current production or to maintain assets on a standby basis are charged to operations. Costs of abandoned projects are charged to operations upon abandonment. During the years ended July 31, 2013 and 2012, the Company recorded exploration costs of $606 and $560, respectively.

F-6

Table of Contents

~~Remmington Enterprises~~Altovida, Inc.

(AnFormerly ~~exploration~~Known ~~stage~~as ~~Company~~Remmington Enterprises, Inc.)

Notes toTo ~~Condensed~~The Consolidated Financial Statements

~~(F)~~Note ~~Impairment~~1 - Nature of ~~Long-Lived~~Business ~~Assets~~and Summary of Significant Accounting Policies

~~The~~Nature Company accounts for its long-lived assets in accordance with ASC Topic 360-10. ASC Topic 360-10 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of ~~an asset may no longer be appropriate.~~Operations

Altovida, Inc. (Fthe "Company") was originally incorporated under the laws of the State of Nevada on July 15, 2011 as Remmington ~~Impairment~~Enterprises, Inc. On October 29, 2014; the Company amended its articles of ~~Long~~incorporation to change its name to Altovida, Inc. On January 16, 2014, the Company’s former CEO and sole director, Mr. G. Andre Scroggins resigned from all positions. In connection with his resignation, the Company entered into an asset purchase agreement whereby Mr. Scroggins acquired all the assets of the Company in exchange for his assumption of all liabilities of the Company as of that date. Simultaneous to the resignation of Mr. Scroggins, Mr. Hans Morgan Van Niekerk was appointed as the Company’s new CEO and sole director. Under the direction of Mr. Van Niekerk, the Company has discontinued its mining activities and re-~~Lived~~directed ~~Assets~~its ~~(Continued)~~business focus in the pharmaceutical industry.

The Company ~~assesses~~has ~~recoverability~~adopted ofa the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset's carrying value and fair value or disposable value. During the period ended July 31, ~~2013,~~year ~~no impairment was recognized~~end.

~~(G)~~Principles ~~Financial~~of ~~Instruments~~ consolidation

~~Financial~~The ~~instruments~~consolidated ~~consist~~financial ofstatements ~~cash,~~include ~~accounts~~the ~~receivable,~~ accounts ~~payable~~of Altovida, ~~notes~~Inc. ~~payable~~ and ~~advances~~Altovida ~~payable~~Biosciences Ltd. All ~~Recorded~~significant ~~values of cash,~~intercompany ~~receivables,~~balances ~~accounts payable~~ and ~~accrued~~transactions ~~liabilities~~have ~~approximate~~been ~~fair~~eliminated. ~~values~~Altovida, ~~due to the short maturities of such instruments~~Inc. ~~Recorded~~ ~~values for notes payable~~ and ~~related~~Altovida ~~liabilities~~Biosciences ~~approximate~~Ltd ~~fair~~will ~~values,~~be ~~since~~collectively ~~their~~referred ~~stated or imputed interest rates~~herein ~~are~~to ~~commensurate~~as ~~with~~the ~~prevailing market rates for similar obligations~~“Company”.

~~(H)~~Use ~~Loss~~of ~~Per Share~~Estimates

The ~~Company~~preparation ~~reports~~of ~~earnings~~financial ~~(loss)~~statements ~~per share~~ in accordance with ~~ASC~~United ~~Topic~~States ~~260-10.~~generally ~~Basic~~accepted ~~earnings~~accounting ~~(loss)~~principles ~~per~~requires ~~share~~management to ismake ~~computed~~estimates ~~by dividing~~and ~~income~~assumptions ~~(loss)~~that ~~available~~affect tothe ~~common~~reported ~~shareholders~~amounts byof assets and liabilities at the ~~weighted~~date ~~average~~of ~~number~~the financial statements and the reported amounts of ~~common~~revenue ~~shares~~and ~~available~~expenses in the reporting period. ~~Diluted~~The ~~earnings (loss)~~Company ~~per~~regularly ~~share~~evaluates isestimates ~~computed~~and ~~similar~~assumptions related to ~~basic~~stock-based ~~earnings~~compensation, ~~(loss)~~and ~~per~~deferred ~~share~~income ~~except~~tax ~~that~~asset ~~the~~valuation ~~denominator~~allowances. isThe ~~increased~~Company tobases ~~include~~its ~~the~~estimates and assumptions ~~number~~on ofcurrent ~~additional~~facts, ~~common~~historical ~~shares~~experience and various other factors that ~~would~~it ~~have~~believes ~~been~~to ~~outstanding~~be ifreasonable under the ~~potential~~circumstances, ~~common~~the results ~~shares~~of ~~had~~which ~~been~~form ~~issued~~the basis for making judgments about the carrying values of assets and ifliabilities and the accrual of costs ~~additional~~and ~~common~~expenses ~~shares~~that ~~were~~are ~~dilutive~~not readily apparent from other sources. AsThe ofactual ~~July~~results ~~31,~~experienced ~~2013,~~by the Company may differ materially and adversely from the Company’s estimates. To the extent there ~~were~~are nomaterial ~~potential~~differences ~~common~~between ~~shares~~the ~~underlying~~estimates ~~warrants~~and orthe ~~options~~actual results, future results of operations will be affected.

~~(I)~~Cash ~~Revenue~~and ~~Recognition~~Cash Equivalents

The Company ~~currently~~considers ~~has~~all ~~not~~highly ~~generated~~liquid ~~revenues.~~temporary ~~Any~~cash ~~future~~investments ~~revenues~~with ~~earned,~~an ~~primarily~~original ~~through~~maturity ~~the sale~~ of ~~extracted~~three ~~minerals,~~months ~~will be~~or ~~recognized~~less ~~utilizing~~to ~~the~~be ~~following~~cash ~~general revenue recognition criteria: 1) pervasive evidence of an arrangement exists; 2)~~equivalents. At ~~delivery~~July ~~has~~31, ~~occurred;~~2014, 3) the ~~price~~Company tohad ~~the~~$210,399 ~~buyer~~in iscash ~~fixed or determinable;~~ and 4)no ~~collectability~~cash ~~is reasonably assured~~equivalents.

~~Delivery~~Property ~~on mineral sales is determined to be complete for revenue recognition purposes when title~~ and risk of loss has passed to the customer in accordance with stated contractual terms and there is no future obligations related to the shipment. Title generally passes as the minerals are loaded into transport carriers for delivery to the customer.Equipment

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (Jgenerally accelerated) ~~Income~~for ~~Taxes~~tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

F-7

Table of Contents

~~Remmington~~Note ~~Enterprises,~~1 ~~Inc.~~- Nature of Business and Summary of Significant Accounting Policies

~~(An~~Property ~~exploration~~and ~~stage~~Equipment, ~~Company)~~continued

~~Notes~~Equipment 3-5 ~~to Condensed Financial Statements~~years

~~(J)~~Furniture ~~Income~~7 ~~Taxes, continued~~years

~~differences~~The ~~are~~Company reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to beresult ~~recovered~~from orits ~~settled~~use and eventual disposition. ~~The~~In ~~effect~~cases onwhere ~~deferred~~undiscounted ~~tax~~expected ~~assets~~future ~~and~~cash ~~liabilities~~flows ofare aless ~~change~~than inthe ~~tax~~carrying ~~rates~~value, an impairment loss is recognized in ~~income~~equal into an amount by which the ~~period~~carrying ~~that~~value ~~includes~~exceeds the ~~enactment~~fair ~~date.~~value ~~When~~of itassets. ~~isconsidered~~The tofactors beconsidered ~~more~~by management ~~likely~~in ~~than~~performing ~~not~~this ~~that~~assessment ainclude ~~deferred~~current ~~tax asset~~operating ~~will~~results, ~~not~~trends beand ~~realized~~prospects, athe ~~valuation~~manner ~~allowance~~in which the property is ~~provided~~used, ~~for~~and the ~~excess~~effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there were no impairments needed as of July 31, 2014.

~~(K) New Accounting Standards~~Inventory

WeInventories doconsist ~~not~~of ~~believe~~merchandise ~~there~~held for sale in the ordinary course of business, including cost of freight and other miscellaneous acquisition costs, and are ~~any~~stated ~~recently~~at ~~issued~~the ~~accounting~~lower ~~standards~~of ~~that~~cost, ~~have~~or ~~not~~market ~~yet~~determined ~~been~~on ~~adopted~~the ~~that~~first-in-first-out ~~will~~basis. The Company records a write-down for inventories, which have become obsolete or are in excess of anticipated demand or net realizable value. The Company performs a ~~material~~detailed ~~impact~~review of inventory each period that considers multiple factors including demand forecasts, market conditions, product onlife cycle status, product development plans and current sales levels. If future demand or market conditions for the Company’s products ~~financial~~are ~~statements~~less favorable than forecasted or if unforeseen changes negatively affect the utility of the Company’s inventory, it may be required to record additional write-downs, which would negatively affect gross margins in the period when the write-downs are recorded. If actual market conditions are more favorable, the Company may have higher gross margins when products incorporating inventory that were previously written down are sold.

~~Note~~Fair ~~2 Going~~Value ~~Concern~~of Financial Instruments

~~The~~Financial ~~accompanying~~instruments ~~financial~~consist ~~statements~~of ~~have~~cash, ~~been~~inventory, ~~prepared~~prepaid onexpenses, aaccounts ~~going concern basis~~payable, ~~which~~and ~~contemplates~~notes ~~the~~payable. ~~realization~~Recorded values of ~~assets~~these ~~and~~instruments ~~the~~approximate ~~satisfaction~~their offair ~~liabilities~~values indue to the ~~normal~~short-term ~~course~~maturities of ~~business~~such instruments. ~~The~~Recorded ~~Company~~values ~~has~~for ~~incurred~~notes apayable ~~net~~and ~~loss~~related liabilities ofapproximate ~~$159~~fair values,~~410~~ ~~for~~since ~~the~~their ~~period of~~stated ~~July~~or ~~15,~~imputed ~~2011~~interest ~~(Inception)~~rates toare ~~July~~commensurate ~~31,~~with ~~2013~~prevailing market rates for similar obligations.

~~These~~Earnings ~~conditions~~(Loss) ~~give~~Per rise to doubt about the Company’s ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional financing or sale of its common stock as may be required and ultimately to attain profitability.Share

~~Note~~The ~~3 Mining~~Company ~~Properties~~reports earnings (loss) per share in accordance with ASC Topic 260-10. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of July 31, 2014, there were no potential common shares underlying warrants or options.

~~On July 26, 2011, the Company acquired four lode mining claims for cash totaling $20,600.~~F-8

~~Note 4 Related~~Table ~~Party~~of ~~Transactions~~Contents

OnNote ~~July~~1 ~~19,~~- ~~2011,~~Nature ~~the Company issued 10,000,000 shares~~ of ~~its~~Business ~~restricted common stock to its sole officer~~ and ~~director~~Summary ~~at a rate~~ of ~~$0.003~~Significant ~~per~~Accounting ~~share. (See NOTE 5)~~Policies

~~Note~~Revenue ~~5 Stockholders’ (Deficit)~~ Recognition

The Company recognized revenue at point of sale of product utilizing the following general revenue recognition criteria: 1) sales order received, and; 2) the price to the buyer is fixed or determinable; and 3) good have been shipped; and 4) collectability is reasonably assured.

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC Topic 740-10. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When it is considered to be more likely than not that a deferred tax asset will not be realized, a valuation allowance is provided for the excess.

Share-Based Compensation

The Company accounts for stock-based payments to employees in accordance with ASC 718, “Stock Compensation” (“ASC 718”). Stock-based payments to employees are currently comprised of restricted stock grants that are recognized in the consolidated statement of operations based on their fair values at the date of grant.

The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and Topic 505-50, “Equity-Based Payments to Non-Employees.” Stock-based payments to non-employees may include grants of stock, stock options and issuances of warrants that are recognized in the consolidated statement of operations based on the value of the vested portion of the award over the requisite service period as measured at its then-current fair value as of each financial reporting date. The fair value of option grants and warrant issuances will be calculated utilizing the Black-Scholes pricing model. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. ASC 718 requires forfeitures to be estimated at the time stock options are granted and warrants are issued to employees and non-employees, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant. The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period. In estimating the forfeiture rate, The Company monitors both stock option and warrant exercises as well as employee termination patterns.

Foreign Currency

The Company accounts for foreign currency in accordance with ASC Topic 830 “Foreign Currency” whereby the local currency is the functional currency. Assets and liabilities of the Company’s foreign locations are translated to reporting currency at the rate of exchange existing at the balance sheet date. Income statement amounts are translated at a weighted average monthly exchange rate for each reporting period. The cumulative translation adjustments resulting from changes in exchange rates are included in the consolidated balance sheet as “Other comprehensive income”, a separate component of stockholders’ equity. Transaction gains and losses are included in the consolidated statement of operations. As of July 31, 2014, the Company recorded other comprehensive loss of $10,958 in accumulated translation adjustments and $7,635 in foreign currency transaction losses.

F-9

Table of Contents

Note 1 - Nature of Business and Summary of Significant Accounting Policies

New Accounting Standards

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued a new accounting statement that reduces some of disclosures and reporting requirements for development stage companies. The change will be in effect for the interim and annual periods beginning after December 15, 2014. As of such date, among other things development stage entities will no longer be required to report inception-to-date information. The company has elected early adoption of this pronouncement and will no longer being reporting inception-to-date information.

There are no other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Note 2 - Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company recorded a net (loss) of $773,522 for the period of November 22, 2013 (inception) to July 31, 2014. These conditions give rise to doubt about the Company’s ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional financing or sale of its common stock as may be required and ultimately to attain profitability per the current business plan.

Note 3 - Business Combination

On May 2, 2014, the Company completed its acquisition of Altovida Biosciences, Ltd. (“Altovida”). In accordance with the terms of the Exchange Agreement, the Company issued 12,280,000 shares of its common stock to the shareholders of Altovida in exchange for all the outstanding stock of Altovida. Due to the change in control and form of consideration given, the transaction is being accounted for as a recapitalization of Altovida. Whereby Altovida is the accounting acquirer and the Company is the legal acquirer. Accordingly, it is the historic financial statements of Altovida retroactively restated giving effect to the accounting recapitalization. There were 15,505,000 shares of the Company’s common stock outstanding before giving effect to the stock issuances in the exchange. Immediately following the exchange, the Company’s majority shareholder cancelled its 12,050,000 shares. In connection with the Share Exchange Agreement, the Company entered into a Lock-Up Agreement with the acquiring shareholders whereby the Company and the shareholders agree to a one year prohibition on the sales or transfers of common stock held by the shareholders.

Note 4 - Related Party Transactions

Services Agreements

On May 2, 2014, the Company appointed three officers of Altovida as officers and directors of the Company and assumed liabilities related to previously issued compensation agreements. Pursuant to the original agreements, effective as of March 1, 2014 provide for annual compensation to each executive of approximately $167,110 (£100,000) and standard employee benefits subject to a probationary period of six-months. The term of the agreement is indefinite but may be cancelled with six month written notice by either party.

F-10

Table of Contents

Note 5 - Notes payable

On May 1, 2014, the Company entered into a Replacement Promissory Note in the amount of $419,000 with Knight Financial, Ltd. (“Knight”) in contemplation of its May 2, 2014 Share Exchange Agreement. Whereas, Altovida previously issued a Senior Secured Bridge Loan in the principal amount of $81,421and received a cash advance in the amount of $50,000 of which Knight agreed to forgive $24,000. The new note was issued by the Company for the purpose of reflecting all amounts owed to Knight and to restate the terms of the aforementioned security agreement. The replacement note bears interest at a rate of 6% per annum, matures on May 1, 2018 and is secured by all the assets of the Company.

As of July 31, 2014, the unpaid principle balance totaled $445,000 and accrued interest amounted to $6,238.

Note 6 - Stockholders’ Deficit

We are authorized to issue up to 90,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock. The Preferred Stock may be issued in one or more series, with all rights and preferences being determined by the board of directors.

Preferred Stock

The voting rights, rate of dividends preference in relation to other classes or series, and rights in the event of liquidation related to shares of Preferred Stock of any series are determined by the board of directors and may vary from time to time.

F-8

Table of Contents

Remmington Enterprises, Inc.

(An exploration stage Company)

Notes to Condensed Financial Statements

Note 5 Stockholders’ (Deficit), continued

Common Stock

Holders of common stock have voting rights equal to one vote for each share of Common Stock held and are entitled to receive dividends when, and if declared by the board of directors subject to the rights of any Preferred Stock having preference as to dividends. In the event of liquidation or dissolution, subject to the rights of Preferred Stock holders are entitled to share ratably in the Corporations assets. Holders of Common Stock do not have conversion, redemption or preemptive rights.

~~On July 19, 2011, the Company issued 10,000,000 shares of its common stock to its sole officer and director for cash totaling $30,000.~~F-11

~~During the~~Table ~~year ended July 31, 2012, the Company issued a total~~ of 3,000,000 shares of its common stock at a price of $0.008 per share for a total of $23,200 cash and $800 in stock subscriptions receivable. In August 2012 the stock subscription receivable of $800 was considered uncollectible and thus has been written off the books utilizing that effective date.Contents

Note ~~7 Subsequent~~6 - ~~Events~~Stockholders’ (Deficit) (Continued)

On May 2, 2014, the Company sold Knight Financial, Ltd. 69,833 common shares at a price of $6 per share, for a total proceeds of $419,000. As of July 31, 2014 the shares were unissued.

On June 20, 2014, the Company issued 37,325,083 shares to its CEO, Michael Richard Hawthorne, and 37,325,083 to its Executive Chairman, Vinod Kaushal at $0.001 per share. The $74,650 due from related parties for the share purchase has not been paid as of July 31, 2014.

Note 7 - Subsequent Events

Subsequent to the period ended July 31, 2014, the Company cancelled a total of 12,280,000 shares held by related parties and originally issued in connection with its acquisition of Altovida. In addition, the Company also accepted a revised subscription agreement from two of its officers whereby the original agreement to purchase a total of 74,650,166 shares or 37,325,083 each, was revised to reflect a total share purchase of 31,492,083 each or a total of 62,984,166. As of the date of this filing, the Company has a subscription receivable due from related parties totaling $62,984.

In accordance with ASC 855, management evaluated all activity of the Company through the issue date of the financial statements and concluded that no other subsequent events have occurred that would require recognition or disclosure in the financial statements.

F-912

Table of Contents

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

No events occurred requiring disclosure under Item ~~307~~304 ~~and 308~~ of Regulation S-K during the fiscal year ending July 31, ~~2013~~2014.

Item 9A. Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this annual report, being July 31, ~~2013~~2014. This evaluation ~~was~~ was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and ~~Chief~~ Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this annual report.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of July 31, ~~2013~~2014 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of July 31, ~~2013~~2014, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending July 31, ~~2014~~2015: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to an exemption for non-accelerated filers set forth in Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Item 9B. Other Information

None

1511

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The following ~~information~~table ~~sets~~contains ~~forth~~information ~~the~~with ~~names,~~respect ~~ages,~~to ~~and positions of~~ our current ~~directors and~~ executive ~~officers~~officer asand ~~of October 25, 2012.~~director:

Name	Age	~~Age~~	~~Position(s)~~Principal ~~and~~Positions ~~Office(s)~~With ~~Held~~Us
Gary A. Scoggins		32	President, Chief Executive Officer, Chief Financial Officer, and Director
Michael Hawthorne		40	President, Chief Executive Officer and Director
Lorna Peers		45	Chief Financial Officer, Treasurer, Secretary and Director
Vinod Kaushal		51	Executive Chairman and Director

~~Set~~The ~~forth~~business ~~below~~address ~~is a brief description~~ of ~~the~~our ~~background~~officers and ~~business~~directors ~~experience~~is ofc/o ~~each~~Altovida, ofInc., ~~our~~BioCity ~~current~~Scotland, ~~executive~~Newhouse, ~~officers~~Lanarkshire, ~~and~~UK ~~directors~~ML1 5UH.

~~Gary~~Our A.directors ~~Scoggins. Mr.~~hold ~~Scoggins~~office ~~was~~for ~~appointed~~one-year asterms ~~our~~or ~~President,~~until ~~CEO,~~their ~~CFO,~~successors ~~and~~have ~~sole~~been ~~Director~~duly ~~concurrently~~elected ~~with~~and ~~his founding~~qualified. ofOur ~~the~~officers ~~company~~are onelected annually ~~July~~by ~~15,~~the ~~2011. Mr.~~board ~~Scoggins~~of ~~has~~directors ~~worked~~and asserve anat ~~independent~~the ~~professional~~discretion ~~barber~~of ~~for~~ the ~~past eleven years~~board. ~~Mr.~~ ~~Scoggins~~Set ~~does~~forth ~~not~~below ~~have~~is ~~any prior experience as~~ a ~~chief~~summary ~~executive~~description orof as the ~~head~~principal occupation ofand abusiness ~~public~~experience ~~company. There are~~of noeach ~~items~~ of ~~specific~~our ~~professional~~directors ~~experience,~~and ~~qualifications,~~executive orofficers ~~skills~~for ~~that~~at ~~led~~least tothe ~~his~~last ~~appointment~~five ~~as our sole officer and director~~years.

~~Directors~~Michael Hawthorne. Michael has been CEO of the Altovida companies since 2013. Having started in the industry with Parke Davis (now Pfizer Inc NYSE:PFE), he went on to hold senior global leadership roles in a range of established and start-up pharma and biotechnology companies including Sangstat Medical Corporation (a NASDAQ company, now Genzyme Inc), Orion Corporation (NASDAQ: ORNAV) and Mitovie Group where he was CEO. Michael has broad product development and global commercialization experience across a range of therapy areas having worked on specialist biological products through to blockbuster drugs. He has completed over 100 licensing and commercial deals.

~~Our~~Lorna ~~bylaws~~Peers. ~~authorize~~Lorna noserved ~~less~~as ~~than~~Finance ~~one~~Director of Angel Biotechnology Holdings plc an AiM listed company from March 2011 to February 2014. Prior to her role with Angel, Lorna held a similar position with Stem Cell Sciences PLC (1LSE and ASE listed). ~~director~~Lorna started her career with the Royal Bank of Scotland Group, going on to hold various group and divisional finance roles in areas including Corporate Finance, Group Internal Audit, Group Management Reporting and Retail Banking. We ~~currently~~Lorna ~~have~~is ~~one~~a ~~Director~~qualified accountant and a Fellow of the Association of Chartered Certified Accountants (ACCA).

~~Term~~Vinod Kaushal. Vinod has been Executive Chairman of ~~Office~~the Altovida companies since 2013. Vinod is a well-seasoned industry executive with over 25 years’ experience in predominantly commercial and general management roles. He has worked nationally, regionally and globally for a number of blue chip and SME companies. This has included global roles with AstraZeneca on Losec®/Prilosec® and Gastroenterology,, Head of global strategy at Novo Nordisk, Vice President of Amersham/GE Health’s Neurology business, Vice President at Royal Numico/Danone and CEO of SPL in the UK amongst other pivotal roles. With an impressive deal sheet to his name, Vinod has been involved in a large number of important drug and business acquisitions. His career has seen him relate to investors on several global stock exchanges.

~~Our~~There ~~Directors~~ are ~~appointed~~no ~~for~~family arelationships ~~one-year~~among ~~term to hold office until the next annual general meeting of~~ our ~~shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of~~ directors and ~~hold~~executive ~~office until removed by the board~~officers.

Significant Employees

We have no significant employees other than our officer and director.

Family Relationships

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

Table of Contents

Involvement in Certain Legal Proceedings

To the best of our knowledge, during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Committees of the Board

WeOur docompany currently does not ~~currently~~have nominating, compensation or audit committees or committees performing similar functions nor does our company have a written nominating, compensation or audit committee charter. Our directors believe that it is not necessary to have such committees, ~~executive~~at ~~committee~~this time, orbecause ~~stock~~the ~~plan~~functions ~~committee~~of such committees can be adequately performed by the board of directors.

~~Audit~~Our ~~Committee~~company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The board of directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees. The board of directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

WeA doshareholder ~~not~~who ~~have~~wishes a separately-designated standing audit committee. The entire Board of Directors performs the functions of an audit committee, but no written charter governs the actions of the Board when performing the functions of what would generally be performed by an audit committee. The Board approves the selection of our independent accountants and meets and interacts with the independent accountants to ~~discuss~~communicate ~~issues related to financial reporting. In addition, the Board reviews the scope and results of the audit~~ with ~~the independent accountants, reviews with management and the independent accountants~~ our ~~annual~~board ~~operating results, considers the adequacy~~ of ~~our~~directors ~~internal~~may ~~accounting~~do ~~procedures~~so ~~and~~by ~~considers~~directing ~~other~~a ~~auditing~~written ~~and~~request ~~accounting~~addressed ~~matters including fees~~ to beour ~~paid~~CEO ~~to the independent auditor~~ and ~~the~~director, ~~performance~~Michael ~~of the independent auditor. Our Board of Directors~~Hawthorne, ~~which~~at ~~performs~~ the ~~functions of~~address anappearing ~~audit~~on ~~committee, does not have a member who would qualify as an “audit committee financial expert” within~~ the ~~definition~~ offirst ~~Item~~page ~~407(d)(5)(ii)~~ of ~~Regulation~~this ~~S-K.~~annual ~~We believe that, at our current size and stage of development, the addition of a special audit committee financial expert to the Board is not necessary~~report.

Nomination Committee

Our Board of Directors does not maintain a nominating committee. As a result, no written charter governs the director nomination process. Our size and the size of our Board, at this time, do not require a separate nominating committee.

When evaluating director nominees, our directors consider the following factors:

· The appropriate size of our Board of Directors;

· Our needs with respect to the particular talents and experience of our directors;

· The knowledge, skills and experience of nominees, including experience in finance, administration or public service, in light of prevailing business conditions and the knowledge, skills and experience already possessed by other members of the Board;

· Experience in political affairs;

· Experience with accounting rules and practices; and

· The desire to balance the benefit of continuity with the periodic injection of the fresh perspective provided by new Board members.

Our goal is to assemble a Board that brings together a variety of perspectives and skills derived from high quality business and professional experience. In doing so, the Board will also consider candidates with appropriate non-business backgrounds.

Table of Contents

Other than the foregoing, there are no stated minimum criteria for director nominees, although the Board may also consider such other factors as it may deem are in our best interests as well as our stockholders. In addition, the Board identifies nominees by first evaluating the current members of the Board willing to continue in service. Current members of the Board with skills and experience that are relevant to our business and who are willing to continue in service are considered for re-nomination. If any member of the Board does not wish to continue in service or if the Board decides not to re-nominate a member for re-election, the Board then identifies the desired skills and experience of a new nominee in light of the criteria above. Current members of the Board are polled for suggestions as to individuals meeting the criteria described above. The Board may also engage in research to identify qualified individuals. To date, we have not engaged third parties to identify or evaluate or assist in identifying potential nominees, although we reserve the right in the future to retain a third party search firm, if necessary. The Board does not typically consider shareholder nominees because it believes that its current nomination process is sufficient to identify directors who serve our best interests.

Code of Ethics

AsWe ofhave ~~October 28, 2013, we had~~ not adopted a Code of Ethics ~~for~~that ~~Financial~~applies ~~Executives, which would include~~ our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

Table of Contents

Item 11. Executive Compensation

~~Compensation~~The ~~Discussion~~table below summarizes all compensation awarded to, earned by, or paid to our officers for all services rendered in all capacities to us for our fiscal years ended July 31, 2014 and ~~Analysis~~2013.

The Company presently not does have employment agreements with its named executive officer and it has not established a system of executive compensation or any fixed policies regarding compensation of executive officers. Due to financial constraints typical of those faced by a exploration stage business, the company has not paid any cash and/or stock compensation to its named executive officer.

Name and Principal Position	Year		Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation Earning ($)		All Other Compensation ($)		Total ($)
Hans Morgan Van Niekerk (1)		2014		0		0		0		0		0		0		0		0 0
Gary A. Scoggins, (2)		2013 2012		0 0		0 0		0 0		0 0		0 0		0 0		0 0		0 0
Michael Hawthorne (3)		2014		88,672		0		0		0		0		0		0		88,672
Lorna Peers (4)		2014		88,672		0		0		0		0		0		0		88,672
Vinod Kaushal (5)		2014		88,672		0		0		0		0		0		0		88,672

~~Our~~(1) ~~sole~~Hans ~~executive~~Morgan ~~officer~~Van ~~holds~~Nielerk ~~substantial~~served ~~ownership~~as ~~in the Company and is motivated by a strong entrepreneurial interest in growing~~ our ~~operations~~Chief ~~and~~Executive ~~potential~~Officer ~~revenue base to the best of his ability. As our business~~ and ~~operations~~Director ~~expand~~until ~~and mature,~~May ~~we expect to develop a formal system of compensation designed to attract~~2, ~~retain and motivate talented executives~~2014.

~~Summary~~(2) ~~Compensation~~Gary ~~Table~~A. Scoggins served as our Chief Executive Officer and Director until January 16, 2014

~~The table~~(3) ~~below~~Represents ~~summarizes all~~ compensation ~~awarded~~earned ~~to,~~as ~~earned~~an ~~by,~~officer orof ~~paid~~Altovida. toOn ~~each~~May ~~named~~2, ~~executive~~2014, ~~officer~~Michael ~~for~~Hawthorne ~~our~~was ~~last~~appointed ~~two~~as ~~completed~~President, ~~fiscal~~Chief ~~years~~Executive ~~for~~Officer ~~all~~and ~~services~~a ~~rendered~~member toof usthe Board of Directors.

SUMMARY COMPENSATION TABLE
Name and principal position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Gary A. Scoggins, CEO, CFO, President, Secretary-Treasurer, & Director	2013 2012	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0

(4) Represents compensation earned as an officer of Altovida. On May 2, 2014, Lorna Peers was appointed as CFO, Secretary, Treasurer and a member of the Board of Directors.

~~Narrative~~(5) ~~Disclosure~~Represents tocompensation earned as an officer of Altovida. On May 2, 2014, Vinod Kaushal was appointed as Chairman and a member of the ~~Summary~~Board ~~Compensation~~of ~~Table~~Directors.

~~Our named~~Narrative ~~executive~~to ~~officer~~Summary ~~does~~Compensation ~~not currently receive any compensation from the Company for his service as an officer of the Company.~~Table

18On March 1, 2014, Altovida entered into employment agreements with its three officers, Michael Hawthorne, Lorna Peers and Vinod Kaushal. The Company agreed to pay £100,000 (approximately $167,110) annual salary to each of the officers, £8,333 (approximately $13,925) monthly.

Director Compensation

As of July 31, 2014, none of our directors or executive officers held unexercised options, stock that had not vested, or equity incentive plan awards.

We have no pension, annuity, bonus, insurance, equity incentive, non-equity incentive, stock options, profit sharing or similar benefit plans.

Upon the closing of the Share Exchange Agreement, Hans Morgan Van Nielerk resigned as the sole director and simultaneously therewith a new board of directors was appointed as set forth above.

Table of Contents

Outstanding Equity Awards At Fiscal Year-end Table

The table below summarizes all unexercised options, stock that has not vested, and equity incentive plan awards for each named executive officer outstanding as of the end of our last completed fiscal year.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
OPTION AWARDS						STOCK AWARDS
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Shares of Stock That Have Not Vested (#)	Market Value of Shares or Shares of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Shares or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Shares or Other Rights That Have Not Vested (#)
Gary A. Scoggins	0	0	0	0	0	0	0	0	0

Compensation of Directors Table

The table below summarizes all compensation paid to our directors for our last completed fiscal year.

DIRECTOR COMPENSATION
Name	Fees Earned or Paid in Cash ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Non-Qualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Gary A. Scoggins	0	0	0	0	0	0	0

Narrative Disclosure to the Director Compensation Table

Our directors do not currently receive any compensation from the Company for their service as members of the Board of Directors of the Company.

Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, ascertain ofinformation ~~October~~regarding ~~28, 2013,~~ the beneficial ownership of our common stock, bytaking ~~each~~into ~~executive~~account ~~officer and~~the ~~director,~~consummation of the Exchange (1) by each person or entity who is known by us to beneficially own more than 5% of ~~the~~ our common stock, (2) ~~and~~ by each of the named executive officers and directors; asand a(3) ~~group.~~by ~~Except as otherwise indicated,~~ all ~~shares~~of ~~are~~the ~~owned~~named ~~directly~~executive officers and ~~the~~directors ~~percentage~~as ~~shown~~a ~~is based on 13~~group,~~000,000~~ ~~shares~~as of ~~common stock issued and outstanding on~~ October 2822, ~~2013~~2014.

Title of class

Name and address of beneficial owner

Amount of beneficial ownership

Percent of class*

Common

Gary A. Scoggins 7582 Las Vegas Blvd. S., Ste. 236 Las Vegas, Nevada 89123

10,000,000

76.92

Common

Total all executive officers and directors

10,000,000

76.92

Common

Other 5% Shareholders

None

Unless otherwise indicated in the footnotes to the following table, each of the stockholders named in the table has sole voting and investment power with respect to such shares of common stock and the address of each of the stockholders listed below is c/o Altovida, Inc., BioCity Scotland, Newhouse, Lanarkshire, UK ML1 5UH.

As used in this table, "beneficial ownership" means the sole or shared power to vote, or to direct the voting of, a security, or the sole or shared investment power with respect to a security (i.e., the power to dispose of, or to direct the disposition of, a security). In addition, for purposes of this table, a person is deemed, as of any date, to have "beneficial ownership" of any security that such person has the right to acquire within 60 days after such date.

NAME OF OWNER	TITLE OF CLASS	NUMBER OF SHARES OWNED (1)	PERCENTAGE OF COMMON STOCK (2)
Michael Richard Hawthorne	Common	37,325,083	48	%
Lorna Peers	Common	0	0	%
Vinod Kaushal	Common	37,325,083	48	%
All executive officers and directors as a group (3 persons)	Common Stock	74,650,166	96	%

~~The~~(1) ~~persons~~Beneficial ~~named~~Ownership ~~above~~is ~~have~~determined ~~full~~in ~~voting~~accordance ~~and investment power~~ with ~~respect to~~ the ~~shares indicated. Under the~~ rules of the ~~Securities~~SEC and ~~Exchange~~generally ~~Commission,~~includes avoting ~~person (~~or ~~group~~investment ofpower with ~~persons)~~respect ~~is deemed~~ to besecurities. aShares ~~"beneficial~~of ~~owner"~~common ofstock asubject ~~security if~~to heoptions or ~~she,~~warrants ~~directly~~currently exercisable or ~~indirectly~~convertible, ~~has~~ or ~~shares the power to vote~~ exercisable or toconvertible ~~direct~~within ~~the~~60 ~~voting~~days ofare ~~such~~deemed ~~security,~~outstanding orfor computing the ~~power~~percentage ~~to dispose~~ of ~~or to direct~~ the ~~disposition~~person ofholding such ~~security. Accordingly,~~option ~~more~~or ~~than~~warrant but ~~one~~are ~~person~~not ~~may be~~ deemed tooutstanding befor acomputing ~~beneficial owner of~~ the ~~same~~percentage ~~security. A person is also deemed to be a beneficial owner~~ of any ~~security,~~other ~~which that~~ person ~~has the right to acquire within 60 days, such as options or warrants to purchase our common stock~~.

⁽²⁾Based upon 77,650,166 shares issued and outstanding on October 22, 2014, plus the number of shares that such individual has the right to acquire within 60 days of such date.

Item 13. Certain Relationships and Related Transactions, and Director Independence

~~Except~~Other asthan ~~set~~the ~~forth~~transactions described below, ~~none~~and ofunder the ~~following~~heading ~~parties~~“Executive ~~has~~Compensation” (or with respect to which such information is omitted in accordance with SEC regulations), since ~~our~~February ~~date~~1, of2013 ~~incorporation~~there have not been, ~~had~~and ~~any~~there ~~material~~is ~~interest~~not currently proposed, ~~direct~~any transaction or ~~indirect,~~series of similar transactions to which we were or will be a participant in which the amount involved exceeded or will exceed $120,000, and in which any ~~transaction~~director, ~~with~~executive usofficer, holder of 5% or inmore of any ~~presently~~class ~~proposed~~of ~~transaction~~our ~~that~~capital stock ~~has~~or any member of the immediate family of any of the foregoing persons had or will ~~materially~~have ~~affect~~a ~~us:~~direct or indirect material interest.

~~Any~~On January of15, ~~our~~2014, ~~directors~~we orentered ~~officers;~~into ~~Any~~an ~~person~~Agreement ~~proposed~~of asConveyance, aTransfer ~~nominee~~and ~~for~~Assignment ~~election~~of asAssets aand ~~director;~~Assumption ~~Any~~of ~~person~~Obligations (the ~~who~~“Agreement”) ~~beneficially~~with ~~owns,~~our ~~directly~~former orsole ~~indirectly,~~officer ~~shares~~and ~~carrying~~director, ~~more~~Gary ~~than~~A. ~~10%~~Scoggins. ofPursuant to the ~~voting~~Agreement, ~~rights~~we ~~attached~~transferred all assets related to our ~~outstanding~~mineral ~~shares~~exploration ofbusiness, ~~common~~including ~~stock;~~our ~~Any~~mining ofclaims, ~~our~~to ~~promoters;~~Mr. ~~Any~~Scoggins. ~~relative~~In orexchange ~~spouse~~for this assignment of ~~any~~assets, ofMr. ~~the~~Scoggins ~~foregoing~~agreed ~~persons~~to ~~who~~assume ~~has~~and ~~the~~cancel ~~same~~all ~~house~~liabilities ~~address~~relating asto ~~such~~our ~~person~~former mineral exploration business.

1. On July 19, 2011 our founder, president, CEO, CFO, and sole director, Gary A. Scoggins, contributed our initial equity capital by purchasing 10,000,000 shares of common stock in exchange for $30,000 at a price of $0.003 per share.

Director Independence

WeFor ~~are~~purposes ~~not~~of adetermining ~~“listed~~director ~~issuer”~~independence, ~~within~~we ~~the~~have ~~meaning~~applied ofthe ~~Item~~definitions ~~407~~set ofout ~~Regulation~~in ~~S-K~~NASDAQ ~~and~~Rule ~~there~~4200(a)(15). ~~are~~Under noNASDAQ Rule ~~applicable~~4200(a)(15), ~~listing~~a ~~standards for~~director ~~determining~~is ~~the~~not ~~independence~~considered ofto ~~our~~be ~~directors.~~independent ~~Applying~~if ~~the~~he ~~definition~~or ofshe ~~independence~~is ~~set~~also ~~forth~~an inexecutive ~~Rule~~officer ~~4200(a)(15)~~or employee of ~~The~~the ~~Nasdaq~~corporation. ~~Stock Market~~Accordingly, ~~Inc.,~~ we do not have ~~any~~an independent ~~directors~~director as of July 31, 2014.

Table of Contents

Item 14. Principal Accounting Fees and Services

~~Below~~Audit Fees: isAudit ~~the~~fees ~~table~~consist of ~~Audit~~fees ~~Fees~~billed ~~(amounts~~for inprofessional ~~US$)~~services ~~billed~~rendered byfor the audit of our ~~auditor~~year-end infinancial ~~connection~~statements ~~with~~and ~~the~~services that ~~audit~~are ofnormally ~~the~~provided ~~Company’s~~in ~~annual~~connection ~~financial statements~~with ~~for~~statutory ~~the~~and ~~years~~regulatory ~~ended:~~filings. Fees incurred were $17,795.

Financial Statements for the Year Ended	Audit Services		Audit Related Fees		Tax Fees		Other Fees
July 31, 2013	$	4,500	$	4,500		—		—
July 31, 2012	$	4,500	$	4,500		—		—

Audit-Related Fees: Audit-related services consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultations concerning financial accounting and reporting standards and were not incurred for 2014 and 2013.

Tax Services Fees: Tax fees consist of fees billed for professional services for tax compliance. These services include assistance regarding federal, state, and local tax compliance. Tax fees were not incurred during the fiscal year ended July 31, 2014.

All Other Fees: Other fees, which were not incurred, would include fees for products and services other than the services reported above.

Table of Contents

PART IV

Item 15. Exhibits, Financial Statements Schedules

(a)

Financial Statements and Schedules

The following financial statements and schedules listed below are included in this Form 10-K.

Financial Statements (See Item 8)

(b)

Exhibits

Exhibit Number	Description
3.1	Articles of Incorporation (1)
3.2	Bylaws(1)
31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Annual Report on Form 10-K for the year ended June 30, 2012 formatted in Extensible Business Reporting Language (XBRL).

~~(1) Incorporated by reference to Registration Statement on Form S-1 filed September 8, 2011.~~15

**Filed herein

Table of Contents

SIGNATURES

InPursuant ~~accordance~~to ~~with~~the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

~~Remmington Enterprises~~Altovida, Inc.

By:	/s/ Gary A. Scoggins
	Gary A. Scoggins
Title:	President
Date:	October 29, 2013

By: /s/ Michael Richard Hawthorne

InMichael ~~accordance~~Richard ~~with Section 13 or 15(d) of the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:~~Hawthorne

By:	/s/ Gary A. Scoggins
	Gary A. Scoggins
Title:	Chief Executive Officer, Chief Financial Officer, and sole Director
Date:	October 29, 2013

President, Chief Executive Officer, Principal Executive Officer,

22By: /s/ Lorna Peers

Lorna Peers

Chief Financial Officer, Principal Financial Officer,

Principal Accounting Officer, and Director

November 21, 2014

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Michael Richard Hawthorne

Michael Richard Hawthorne

President, Chief Executive Officer, Principal Executive Officer

November 21, 2014

By: /s/ Lorna Peers

Lorna Peers

Chief Financial Officer, Principal Financial Officer,

Principal Accounting Officer, and Director

November 21, 2014

By: /s/ Vinod Kaushal

Vinod Kaushal

Executive Chairman and Director

November 21, 2014

Filing Compare · Altovida Inc.